Skip to main content Accessibility help
×
Home
Hostname: page-component-5d6d958fb5-jlrq2 Total loading time: 2.873 Render date: 2022-11-29T01:07:39.081Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Examining the relationship between nutrition and cerebral structural integrity in older adults without dementia

Published online by Cambridge University Press:  31 October 2018

J. M. Reddan*
Affiliation:
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Melbourne, VIC 3122, Australia
H. Macpherson
Affiliation:
Institute for Physical Activity and Nutrition, Deakin University, Burwood, Melbourne, VIC 3125, Australia
D. J. White
Affiliation:
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Melbourne, VIC 3122, Australia
A. Scholey
Affiliation:
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Melbourne, VIC 3122, Australia
A. Pipingas
Affiliation:
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Melbourne, VIC 3122, Australia
*
*Corresponding author: Jeffery Michael Reddan, email jreddan@swin.edu.au
Rights & Permissions[Opens in a new window]

Abstract

The proportion of adults aged 60 years and over is expected to increase over the coming decades. This ageing of the population represents an important health issue, given that marked reductions to cerebral macro- and microstructural integrity are apparent with increasing age. Reduced cerebral structural integrity in older adults appears to predict poorer cognitive performance, even in the absence of clinical disorders such as dementia. As such, it is becoming increasingly important to identify those factors predicting cerebral structural integrity, especially factors that are modifiable. One such factor is nutritional intake. While the literature is limited, data from available cross-sectional studies indicate that increased intake of nutrients such as B vitamins (for example, B6, B12 and folate), choline, n-3 fatty acids and vitamin D, or increased adherence to prudent whole diets (for example, the Mediterranean diet) predicts greater cerebral structural integrity in older adults. There is even greater scarcity of randomised clinical trials investigating the effects of nutritional supplementation on cerebral structure, though it appears that supplementation with B vitamins (B6, B12 and folic acid) or n-3 fatty acids (DHA or EPA) may be beneficial. The current review presents an overview of available research examining the relationship between key nutrients or adherence to select diets and cerebral structural integrity in dementia-free older adults.

Type
Review Article
Copyright
© The Authors 2018 

Introduction

The proportion of the global population aged 60 years and over is expected to increase over the coming decades. In a recent report by the UN, the number of adults aged 60 years or more in the USA is expected to rise from 74·6 million in 2015 to 122·7 million by 2050(1). Multiple studies have indicated that older adults demonstrate markedly reduced cerebral structural integrity than younger adults, which in turn predicts poorer cognitive functioning(2–5). As such, the identification of factors associated with cerebral structural integrity is paramount. Moreover, if these factors are modifiable, they may be targeted by therapeutic interventions to support cerebral structural integrity and therefore cognitive function with age.

There is a growing literature indicating that nutritional intake may be a pertinent factor influencing the structural integrity of the cerebrum. In the present review, we initially discuss how cerebral structure changes with age but also how such change relates to cognitive functioning. Following this, we discuss the extent to which dietary intake (inferred by FFQ or blood biomarker concentrations) of B vitamins (predominately B6, B12, and folate/folic acid), choline, n-3 fatty acids (n-3-FA) or vitamin D predicts cerebral structural integrity in dementia-free older adults. We will also discuss whole diets such as Mediterranean- (MeDI) and Western-style diets (WeDI), and whether adherence to these dietary patterns predicts cerebral structure. Although the majority of studies within the current literature, and therefore the present review, are cross-sectional or prospective by design, we also discuss the limited number of randomised clinical trials (RCT) that have been performed in this field. Overall, we suggest that nutritional intake is a key lifestyle factor that may have the potential to modify the trajectory of cerebral structural integrity with age.

Cerebral structural integrity in older adults without dementia

MRI has been widely used to investigate cerebral structural integrity changes with age, as well as how such change relates to cognition. The most common measures of cerebral structural integrity include whole or regional cerebral volumes (total volume or compartmentalised grey and white matter (WM) volumes), cortical thickness (CT; the thickness of the cerebral cortex; globally and regionally) as well as the presence and volume of WM hyperintensities (WMH). WMH are bright, or hyper-intense, foci on fluid attenuated inversion recovery (FLAIR) MRI scans, typically due to extensive myelin and axonal deterioration(6,7).

While each of the aforementioned methods are useful for examining large-scale changes to cerebral structure (cerebral macrostructure), they are poorly suited for examining cerebral structure at the microscopic level (cerebral microstructure). For investigating the latter, an MRI methodology termed diffusion tensor imaging (DTI) is frequently utilised. The most common DTI metrics describing cerebral microstructural integrity are fractional anisotropy (FA) and mean diffusivity (MD). Higher FA and lower MD values are suggestive of more intact cerebral microstructure(8). However, FA and MD are summary measures and provide little detail regarding the factors underpinning microstructural decay. To this end, the DTI metrics radial diffusivity (RD) and axial diffusivity (AxD) are often examined. Data derived from rodent studies have revealed that axonal damage appears to facilitate reduced AxD(9–11) whereas demyelination appears to trigger increased RD(12,13). In the present review, poorer cerebral structural integrity refers to relative reductions in whole/regional cerebral volumes, increased frequency or volume of WMH, or poorer global, regional or tract specific microstructural integrity as measured by FA, MD, RD or AxD using DTI.

Cerebral macrostructural integrity in cognitively normal adults

Cross-sectional and longitudinal studies have observed a robust trend towards reduced total cerebral volume (TCv) with increasing age(14–19), with the annual decline in TCv estimated to be between 0·28 and 0·55%(16,20,21). Senescence-related structural decline is evident throughout each cerebral lobe in cognitively normal adults(18,22–25) though frontal and parietal lobes appear to exhibit the greatest decline with increasing age(18,22).

Contributing to changes in TCv are declines to both total and regional grey matter (GM) volumes. A range of studies report that GM volume demonstrates linear decline with increasing age(5,14–16,22,26–29), whereas others report non-linear deterioration indicative of accelerated atrophy typically after midlife(30,31). Overall, age-related reductions in GM volume appear to be relatively widespread with reduced volume having been identified within frontal regions including the superior, middle and inferior frontal gyri as well as orbito-frontal cortex; temporal regions such as the inferior, middle and superior temporal gyri in addition to the temporoparietal junction; superior and inferior parietal lobes; and various occipital zones(5,17,25,26,29,30,32–42). Likewise, medial temporal volumes (i.e. entorhinal cortex, hippocampus and parahippocampus) demonstrate decline with increasing age in cognitively normal older adults(14,19,21,22,24,25,30,37,41,43–45).

Similar to GM, cerebral WM volume is reduced in older adults relative to younger adults. However, unlike GM where atrophy may be evident from young adulthood onwards(35), reductions in WM volume are typically apparent from midlife (4th to 6th decade), before which volume typically increases(16,22,23,31,45–47). In addition, the frequency and volume of WMH located within deep (periventricular) and subcortical WM increases with age(4,19,48–51), especially within the frontal and temporal lobes(4).

Cerebral microstructural integrity in cognitively normal older adults

Cerebral microstructural integrity also demonstrates decline with increasing age. Compared with younger adults, cognitively normal adults demonstrate reduced FA and increased MD(2,3,47,52–63), as well as increased RD(2,47,54,55,58,60,62) throughout cerebral WM. Conversely, regional increases and decreases in AxD have been observed in cognitively normal older adults relative to their younger counterparts(55). Poorer cerebral microstructural integrity in older adults (reduced FA, increased MD, or increased RD), compared with young adults, is evident within association (cingulum, fornix, superior/inferior longitudinal and orbito-frontal fasciculi, uncinate and perpendicular fasciculi), commissural (corpus callosum) and projection fibre tracts (corona radiata, and internal capsule)(2,57,58,61,62,64–70). These findings indicate that senescence-related microstructural decline within the brain of cognitively normal adults is quite pervasive.

Cerebral structural integrity in older adults with age-associated memory impairment or mild cognitive impairment

While there are many data demonstrating reduced cerebral structural integrity in cognitively normal adults with increasing age, other work has identified a greater magnitude of decline in adults with conditions such as age-associated memory impairment (AAMI) or mild cognitive impairment (MCI). Compared with cognitively normal adults, older adults diagnosed with MCI typically demonstrate greater reductions in TCv(32,71,72) as well as increased atrophy within frontal, parietal, temporal, and medial temporal lobes(73–82). A previous systematic review has similarly demonstrated smaller hippocampal volumes in older adults with AAMI compared with their cognitively normal counterparts(73).

Likewise, degradation of cerebral WM appears to be greater in adults with MCI than those deemed cognitively normal. Across older adults, diagnosed as cognitively normal or as having MCI or Alzheimer’s disease, Smith et al. (83) observed a trend of increasing WMH volume with clinical progression of cognitive dysfunction (cognitively normal < MCI < Alzheimer’s disease). Similar observations have been made by a number of other groups comparing cognitively normal older adults and those with MCI(78,84–86).

There also appears to be an increased magnitude of cerebral microstructural deterioration in adults diagnosed with MCI. Multiple studies have observed comparatively lower FA, as well as increased MD and RD in adults with MCI compared with those with normal cognitive functioning(87–99). Further, increased MD, RD and AxD as well as reduced FA scores are apparent within the WM of the fornix and temporal stem of older adults with MCI compared with those with AAMI(100).

Cerebral structure and cognitive performance in older adults without dementia

In a number of studies, poorer cerebral structural integrity appears to predict poorer cognitive performance. In cognitively normal adults, or those with MCI, lower total/regional GM volumes and reduced CT have correlated with reduced processing speed, as well as poorer global functioning, memory performance and executive functioning(4,5,27,42,78,79,82,101–104). Within these same groups, reductions in WM volume as well as an increased number of WMH predicted reduced processing speed as well as poorer global functioning, executive function, problem solving, memory performance and learning ability(7,49,51,83,84,101,105–108).

The quality of cerebral microstructure also appears to be a strong predictor of cognitive performance in dementia-free older adults. Poorer cerebral microstructure, indicated by decreased FA or increased MD or RD, has been correlated with poorer processing speed, executive functioning, problem solving, cognitive flexibility, inhibition and reasoning, pattern recognition, verbal fluency, as well as learning and memory(2,3,49,64–68,88,91,92,95,98,99,109–123).

Summary

Poorer cerebral structural integrity is apparent with increasing age. However, change does not appear unitary, with adults with conditions such as AAMI or MCI typically demonstrating greater cerebral structural decline than cognitively normal adults. Importantly, in each of these cohorts, poorer cerebral structural integrity appears to be correlated with reduced cognitive performance across multiple domains.

Nutritional intake and cerebral structural integrity in older adults without dementia

Although cerebral structural integrity declines with increasing age, there is also increasing evidence that persistently held lifestyle factors may influence the rate of decline. One such factor appears to be nutritional intake. While the current literature is limited, and of varying quality, the nutrients that have been investigated as potential predictors of cerebral structural integrity include B vitamins (particularly B6, B12 and folate), choline, n-3-FA and vitamin D. Adherence to prudent (for example, MeDI) or unhealthy diets (for example, WeDI) has also been investigated as a possible predictor of cerebral structure, as has the consumption of certain whole foods (for example, fish or alcohol). There is even greater scarcity of RCT examining the effects of nutritional supplementation on cerebral structural integrity. To date, only supplementation with B vitamins (i.e. B6, B12 and folate), n-3-FA or polyphenols (specifically resveratrol) has been investigated as a means of modifying cerebral structural integrity in dementia-free older adults.

The following is an overview of cross-sectional and longitudinal studies examining the relationship between the intake of key nutrients (inferred by FFQ or blood biomarker concentrations) and cerebral structural integrity in older adults. While some studies do not report whether their samples included dementia patients, only those involving dementia-free samples (or mixed groups which either adjusted for dementia diagnosis or repeated analysis following their exclusion) are summarised in online Supplementary Table S1. In addition to the overview of cross-sectional and longitudinal studies, an exhaustive review of available RCT investigating nutritional supplementation and cerebral structure in dementia-free adults is provided below. These specific RCT are summarised in Table 1.

Table 1 Randomised clinical trials examining cerebral structure following chronic nutritional supplementation in older adults without dementia (presented in reverse chronological order and by nutrient type)

DF, dementia free; T, treatment group: P, placebo group; VIT-B12, vitamin B12; ↓, lower/reduced; TCv, total cerebral volume; WMv, white matter volume; MCI, mild cognitive impairment; NR, not reported; VIT-B6, vitamin B6; TCar, total cerebral atrophy rate; n-3-FA, n-3 fatty acid; HcY, homocysteine; GM, grey matter; med-TL, medial temporal lobe; HC, hippocampus; paraHC, parahippocampus; rsP, retrosplenial precuneus; LG, lingual gyrus; FFG, fusiform gyrus; CrB, cerebellum; aCingC, anterior cingulate cortex; pirifC, piriform cortex; PFC, prefrontal cortex; ↑, higher/increased; HCv, hippocampal volume; H, healthy; GMv, grey matter volume; preC, precuneus; postCC, postcentral gyrus; IPG, inferior parietal gyrus; STG, superior temporal gyrus; MTG, middle temporal gyrus; WM, white matter; aCC; anterior corpus callosum; UF, uncinate fasciculus; IFOF, inferior fronto-occipital fasciculus; SFOF, superior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; RESV, resveratrol.

* Structural MRI only performed post-intervention.

Participants only screened with the Mini-Mental State Examination, of which only six scored <25 (3 % of sample; treatment group range, 19–30; placebo group range, 24–30; no significant difference between groups).

Structural MRI performed pre- and post-intervention.

§ Structural MRI and diffusion tensor imaging performed pre- and post-intervention.

B vitamins

B group vitamins, specifically vitamins B6, B12 and folate, are readily available from a number of different whole foods. Vitamin B6 is available from meat (including organ meats), but also eggs, nuts, soya beans, and vegetables such as potatoes. The best food sources for vitamin B12 appear to be meat or meat products (for example, milk, cheese or eggs) whereas folate may be obtained through the consumption of foods such as dark green vegetables (for example, broccoli and spinach), as well as asparagus and liver(124). The aforementioned B vitamins are also obtainable through the consumption of dietary supplements, fortified cereals and beverages.

Similar to other nutrients, estimating the mean dietary intake of B vitamins is possible through the accurate administration and scoring of an FFQ or nutrition diary. The extent to which B vitamins are ingested in the diet may also be reflected by specific blood biomarkers. Aside from concentrations of these vitamins in plasma, blood biomarkers used to infer B vitamin intake (specifically B6, B12 and folate) include holotranscobalamin (holoTC), transcobalamin (TC), methylmalonic acid (MMA) and homocysteine (HcY). Higher concentrations of holoTC and TC are indicative of greater ingestion of vitamin B12. Conversely, higher concentrations of MMA may reflect a poorer intake of vitamin B12, while elevated HcY may reflect deficient or insufficient intake of vitamin B6, B12 or folate(125–127).

In an early cross-sectional study, Erickson et al. (128) determined mean intake of vitamins B6 and B12 in a sample of healthy community-dwelling older adults using a 3 d nutrition diary. In their analysis, greater estimated intake of vitamin B6 was correlated with increased GM volume of the anterior and posterior cingulate cortices, medial parietal cortex, left parietal lobe, supplementary motor area, as well as bilateral superior frontal and middle temporal gyri. Conversely, increased estimated intake of vitamin B12 only correlated with increased GM volume within the posterior parietal lobe. Interestingly, the associations with vitamins B6 and B12 were only evident when examining estimated intake from diet and dietary supplementation, not diet alone. This would suggest that intake from supplementation was responsible for these effects.

More recently, others have examined cerebral macrostructural integrity in relation to B vitamin blood biomarkers. In a study of 107 healthy older adults, aged 61–87 years, Vogiatzoglou et al. (126) observed that low concentrations of plasma vitamin B12, holoTC and TC predicted greater global cerebral atrophy, though no relationship was observed for MMA or HcY levels following covariate adjustment. Conversely, Tangney et al. (129) observed that higher serum HcY and MMA levels correlated with lower TCv. Similarly, de Lau et al. (130) has also observed greater WMH volume co-occurring with lower concentrations of plasma B12, HoloTC, and TC, as well as increased MMA. More recently, Köbe et al. (131) examined hippocampal microstructural integrity in adults with MCI with different levels of serum vitamin B12. Köbe et al. (131) identified lower microstructural integrity (increased MD) within the dentate gyrus (DG) as well as cornu ammonis 4 (CA4) in adults with low-normal serum vitamin B12 (<304 pmol/l) compared with adults with higher concentrations (≥304 pmol/l). The association between vitamin B12 and the microstructure of DG and CA4 also partially mediated the relationship between vitamin B12 and memory performance.

Blood HcY concentration appears to be a particularly robust predictor of cerebral structural integrity in older adults. Greater ventricular volume, lower regional GM volumes, and elevated rates of cortical or total cerebral atrophy are evident in older adults with higher HcY(132–137). Likewise, Rajagopolan et al. (138) identified a negative association between frontal, parietal and occipital lobe WM volumes and HcY, even after controlling for participant cognitive function (cognitively normal, MCI or Alzheimer’s disease). Specifically, for every 5 µmol/l increase in HcY, TCv was reduced by 4·4%. However, these effects were restricted to adults with MCI during subgroup analysis. More recently, Madsen et al. (139) examined the correlation between plasma HcY, CT, cortical GM volume and cortical surface area in a large sample of older adults with varying levels of cognitive function (normal cognitive function, MCI or Alzheimer’s disease). Although no relationship was observed between HcY and cerebral structure when considering each group separately, when all participant data were collated (controlling for age, sex and diagnosis), higher HcY predicted reduced CT as well as cortical GM volume, but not surface area, in multiple regions within the frontal, parietal and temporal lobes. Similarly, others have identified a negative correlation between HcY and hippocampal volume in dementia-free older adults aged 60 to 91 years(133,140,141). Higher HcY concentrations have also been correlated with an elevated rate of WM atrophy, as well as an increased frequency and severity of WMH and silent brain infarcts(129,140,142–148). Several other studies using DTI have also observed elevated HcY predicting poorer cerebral microstructure(149,150).

Several RCT have also investigated whether chronic supplementation with B vitamins (B6, B12, and folic acid) influences cerebral structural integrity in older adults. In the Homocysteine and B vitamins in cognitive impairment (VITACOG) trial, adults diagnosed with MCI were administered an oral B vitamin supplement (B6 20 mg/d; B12 0·5 mg/d; folic acid 0·8 mg/d) for 2 years. Several secondary analyses of VITACOG trial data identified that B vitamin supplementation supported cerebral structural integrity through reducing the rate of total cerebral atrophy, as well as GM atrophy within the frontal, temporal and medial temporal lobes(151,152). These effects appear to be greatest in adults demonstrating biological compliance (increased vitamin B12 or folate status), who also exhibited higher baseline HcY levels.

In a more recent analysis of VITACOG trial data, Jernerén et al. (153) likewise observed that B vitamin treatment appeared to reduce cerebral atrophy rate in adults diagnosed with MCI. However, these effects varied depending on baseline n-3-FA status and HcY concentrations. Whilst no significant treatment effect on cerebral atrophy was evident in adults with low baseline n-3-FA status or HcY concentrations (<11·3 µmol/l), B vitamin treatment appeared to reduce cerebral atrophy rate by 40% in adults with high n-3-FA status. n-3-FA status also appeared to modify the cerebral effects following B vitamin treatment in adults with high baseline HcY concentrations (≥11·3 µmol/l). Specifically, cerebral atrophy rate was reduced by approximately 70% following B vitamin treatment in adults demonstrating elevated HcY concentrations at baseline in addition to high n-3-FA status, whilst no effect was apparent in those adults with low n-3-FA status. Similar observations were made by Oulhaj et al. (154) using VITACOG trial data, though for cognitive performance.

A second RCT examining cerebral structural integrity in response to chronic B vitamin supplementation is the MRI substudy of the B-vitamins for the Prevention Of Osteoporotic Fractures (B-PROOF) trial(155). In the B-PROOF trial, 218 adults aged 65 years and over received a daily oral dose of B vitamins (B12 0·5 mg/d; folic acid 0·4 mg/d) for a period of 2 years. Although the sample did include some adults with a Mini-Mental State Examination (MMSE) score less than 25 (treatment group range, 19–30; placebo group range, 24–30; no significant difference between groups), there were only six such adults in total (3% total population), with four receiving B vitamins. In the absence of other diagnostic tests, it appears that the sample, as a whole, was largely dementia free (summarised in Table 1). Moreover, biochemical analysis indicated that the whole sample had elevated HcY levels (range 12–50 μmol/l).

Analysis of B-PROOF data indicated that HcY and MMA concentrations were reduced, whilst serum concentrations of vitamin B12, folate and holoTC were increased in the adults who received B vitamin supplementation. Contrary to the findings of the VITACOG trial, TCv was significantly lower in the B vitamin group compared with placebo. There was also a non-significant (P=0·07) trend towards lower WM volume in the treatment group. However, it is important to note that MRI scans in the B-PROOF study were only performed post-supplementation, whereas all VITACOG trial analyses(151–153) included MRI at pre- and post-supplementation time points. Subsequently, there is no certainty as to whether there were any differences in cerebral structure between the groups before receiving either B vitamins or placebo. Further, the absence of pre-supplementation scans makes it impossible to determine whether supplementation with B vitamins (B12 and folic acid) modified the trajectory of cerebral decline over the 2-year supplementation period.

Given the apparent association between cerebral structural integrity and cognition, it is possible that B vitamin supplementation, via reducing HcY, benefits cognitive function in older adults. However, in a recent meta-analysis combining eleven large trials and approximately 22 000 participants, Clarke et al. (156) observed that while B vitamin supplementation was efficacious for lowering HcY concentrations, it had no significant effect upon global cognitive function, individual cognitive domains, or cognitive ageing.

Two recent reviews(157,158) have discussed a number of important methodological weaknesses with the meta-analysis of Clarke et al. (156), thereby indicating that Clarke et al.’s(156) conclusion that HcY lowering via B vitamin treatment does not benefit cognitive ageing was premature. For example, Smith & Refsum(158) highlight that cognitive decline could not be measured for most participants in the included trials, as baseline global cognitive measures were unavailable for 76% of 20 431 participants. Moreover, McCaddon & Miller(157) highlight that many of the tests used to assess cognitive function in the included trials (for example, MMSE) were designed to function as screening tests and are not necessarily sensitive enough to detect the small, yet clinically relevant changes in cognitive function over time (or following interventions seeking to slow decline over time). The selection of low-sensitivity tasks probably limited the extent to which differences in cognitive function between treatment groups over time were detectable. The reviews by McCaddon & Miller(157) and Smith & Refsum(158) also discuss the findings from several clinical trials which conflict with Clarke et al.’s(156) interpretation of results. For example, in the Folic Acid and Carotid Intima-media Thickness (FACIT) trial(159), 2 years’ daily supplementation with folic acid (800 µg) appeared to improve memory performance and processing speed in adults aged 50–70 years with elevated HcY (>13 µmol/l). Likewise, de Jager et al. (160) observed that in older adults with MCI demonstrating elevated HcY (>11·3 µmol/l), chronic B vitamin supplementation preserved verbal episodic memory performance, whilst improving semantic memory performance. These conflicting observations indicate that additional, well-designed clinical trials are required to delineate whether B vitamin supplementation is efficacious for modifying cognitive function or slowing the rate of cognitive decline over time in older adults currently without dementia.

It is likely that benefits to cognition following reduced HcY may occur in response to benefits to cerebral structural integrity. Douaud et al. (151) performed Bayesian network analysis on VITACOG trial data, determining a causative chain of events by which B vitamin supplementation reduced the rate of cognitive decline in older adults. Specifically, it was determined that B vitamin supplementation altered plasma vitamin B12 and folate concentrations, with vitamin B12 modifying (lowering) HcY levels. This directly facilitated a reduction in cerebral GM atrophy over time, subsequently slowing the rate of cognitive decline. Future well-designed RCT should investigate these effects further.

Choline and choline-containing glycerophospholipids

Choline is another nutrient whose level of dietary ingestion may exert an influence on cerebral structural integrity in older adults. There are a number of different foods containing choline regularly consumed in most people’s diet. These include red meat (as well as organ meats), poultry, fish, eggs and milk. Vegetables such as tomatoes, potatoes, soya beans and broccoli are also good sources of choline(161,162). Choline in the diet appears to be mostly incorporated within phospholipids, such as the glycerophospholipid (GPL) known as phosphatidylcholine (PC)(161,162). There are also various supplements supplying PC sourced from animal products or vegetables(163).

Supplementation with choline, or GPL containing choline, may benefit cerebral structural integrity via an effect upon HcY concentrations. Choline helps regulate HcY levels through the betaine–homocysteine methyltransferase pathway, whereby choline is initially oxidised to betaine (also obtainable from the diet). Betaine, through a reaction mediated via the enzyme betaine-homocysteine methyltransferase, then donates a methyl group, thereby facilitating the conversion of HcY to methionine(164). Choline and betaine intake have been observed to negatively correlate with HcY concentrations in adults aged 30–55 years(161). Similar observations have been made using data from the Framingham Heart Study. In this later investigation, Cho et al. (162) identified that dietary choline soured from PC was negatively correlated with HcY levels. However, after multivariate adjustment, only choline derived from dietary glycerophosphocholine, phosphocholine and sphingomyelin significantly predicted HcY levels.

Others have sought to reduce HcY through PC supplementation. In males aged 50–71 years with elevated HcY (11·0–23·1 μmol/l), Olthof et al. (164) observed a significant reduction in HcY by 18% after only 2 weeks of daily supplementation with 34·0 g of soyabean lecithin, whereby PC was the only GPL present. As such, it is possible that supplementation with choline or choline-containing GPL (in high enough doses) may benefit cerebral structural integrity in a similar way to B vitamins (i.e. B6, B12 or folic acid)(165).

Although choline intake is negatively related to HcY concentrations, choline has not yet been subject to any RCT investigating its effects upon cerebral structure in older adults. In fact, the only work examining cerebral structure in relation to choline intake is a cross-sectional analysis of Framingham Heart Study data by Poly et al. (166). In this study, Poly et al. (166) observed that in adults aged 36–83 years, greater intake of dietary choline (FFQ) was associated with lower WMH volume.

While human data linking choline intake and cerebral structural integrity are limited, there is some evidence from animal studies suggesting beneficial effects. Crespo et al. (167) administered a daily dose (150 mg/kg) of cytidinediphosphocholine (CDP-choline; the precursor to PC produced de novo via the CDP–choline pathway) to young (aged 12 months) and old (aged 24 months) rodents for 12 months. Crespo et al. (167) identified improved hippocampal morphology in older rodents that received supplementation, with hippocampal cells more closely resembling those of the younger rodents rather than those drawn from the aged control group. Similarly, Qu et al. (168) orally administered low, medium or high doses (0·05 g/kg, 0·1 g/kg or 0·2 g/kg, respectively) of PC derived from Sthenotuethis oualaniensis (purple squid) spawns to adult rodents for a period of 30 d. Before PC administration rodents received an intracerebral injection of amyloid-β25–35, which facilitated impaired hippocampal morphology and cognitive functioning. However, PC supplementation appeared to repair hippocampal cells, while also improving learning and memory, as measured by performance on the Morris water maze.

n-3 Fatty acids

n-3-FA are major components of all cellular membranes, with species such as DHA being especially prevalent within neuronal membranes(169). However, in several studies, the concentration of DHA within GPL of rodent neural tissue has been observed to decrease with age(170,171). Similar observations have been made in human cerebral tissues(172), though other work demonstrates either increases(173), or no change(174) in cerebral DHA concentrations with increasing age. However, the concentrations of DHA within cerebral tissue also appear to be influenced by dietary intake of n-3-FA. While the levels of unsaturation within neuronal tissue is tightly controlled, dietary insufficiency or deficiency of n-3-FA may lead to increased concentrations of n-6 fatty acids (n-6-FA) such as docosapentaenoic acid (n-6-FA variant) in place of DHA(169), though animal data suggest that these effects may be corrected through dietary modification(175). Importantly, while the short-chain n-3-FA α-linolenic acid may be converted to longer-chain n-3-FA such as DHA, the rate of conversion is low, and subsequently, it may be more efficient to consume whole foods or supplements rich in DHA for boosting the concentrations of this n-3-FA in cerebral tissue(176).

Long-chain n-3-FA such as DHA, but also EPA, may be obtained by consuming marine foods such as oily fish, but also through supplementation (for example, fish oil or krill oil). n-3-FA may also be sourced from bovine (cow) or pig brain where they are stored in GPL form(177–179). Moreover, supplementation with n-3-FA derived from marine or terrestrial (i.e. bovine or pig brain) sources has been shown to elevate the concentrations of n-3-FA within both erythrocytes and neuronal tissues(178–183).

Given that fish, especially oily fish, is a rich source of n-3-FA such as DHA, it is plausible that fish consumption in older adults is predictive of cerebral structural integrity. Indeed, higher fish consumption has been correlated with greater GM volume within the orbitofrontal cortex, posterior cingulate, precuneus and hippocampus in cognitively normal older adults(184). Similarly, elevated fish consumption also predicts lower prevalence of subclinical infarcts and greater WM macrostructural integrity in adults aged 60 years and over(185,186).

Other research has examined the extent to which n-3-FA status predicts cerebral integrity in older adults. Greater plasma n-3-FA status has been associated with larger global GM volumes(187) as well as reduced cortical atrophy or GM degradation within medial temporal structures including the hippocampus, parahippocampus and amygdala(188,189). Likewise, a greater concentration of plasma n-3-FA has been correlated with superior WM macrostructural integrity, with studies observing reduced subclinical infarcts and lower WMH volume with elevated n-3-FA concentrations(190,191).

Although plasma concentrations of n-3-FA may be a useful for predicting cerebral structural integrity, one pertinent issue associated with this measure is that it may be influenced by short-term fluctuations in n-3-FA consumption(192). As such, it may not be an accurate reflection of long-term n-3-FA ingestion. Conversely, the concentration of n-3-FA within erythrocyte membranes may be a better reflection of chronic n-3-FA intake(193).

In a study incorporating over 1111 postmenopausal females, aged 65–80 years, Pottala et al. (194) observed an increased TCv of 2·1 cm3 with each 1 sd increase in erythrocyte-bound n-3-FA (DHA + EPA). Similarly, Pottala et al. (194) also observed greater hippocampal volume in older adults with the highest n-3-FA (DHA + EPA) concentrations compared with those with the lowest. In another study, Tan et al. (195) observed lower TCv, as well as increased WMH volume in older adults (mean age 67 (sd 9) years) whose erythrocyte DHA concentrations were in the lowest quartile compared with those whose concentrations were in the higher quartiles (quartile 2 to quartile 4).

Perhaps the most recent study on linking fatty acid status and cerebral structural integrity is Zamroziewicz et al. (196). The authors performed principal components analysis using thirteen different plasma phospholipid-bound fatty acids to delineate whether optimal cerebral structural integrity and cognitive functioning are dependent upon specific fatty acid profiles. Three separate fatty acid profiles were identified. The first profile comprised three n-6-FA and two n-3-FA and was subsequently designated as the long-chain PUFA (LC-PUFA) profile. The second and third fatty acid profiles primarily consisted of n-6-FA, and n-3-FA, respectively. Interestingly, only the LC-PUFA profile was positively associated with microstructural integrity within the fornix. Moreover, LC-PUFA score was positively associated with memory performance, though fornix microstructural integrity appeared to mediate the relationship between LC-PUFA and memory. This appears to support the contention that nutritional intake may influence cerebral structural integrity, and that these effects may further promote cognitive benefits.

Further evidence suggesting that increased n-3-FA intake is neuroprotective comes from a prospective study by Daiello et al. (197). These authors observed greater hippocampal and cortical volumes in cognitively normal adults, as well as in those with MCI and Alzheimer’s disease, who self-reported the use of fish oil supplements over a 3- to 4-year follow-up period (controlling for baseline diagnosis). These results reflect those from a previous RCT whereby cognitively normal adults, aged 50–75 years, were administered a daily n-3-FA supplement for 6 months. Compared with placebo, Witte et al. (198) observed that chronic high-dose n-3-FA supplementation (total n-3-FA dose 2·2 g/d; DHA 880 mg/d; EPA 1320 mg/d) facilitated increased regional cerebral GM volumes as well as improved cerebral microstructural integrity as reflected by increased FA, as well as decreased MD and RD using DTI. More recently, Zhang et al. (199) administered n-3-FA (2000 mg/d algae-derived DHA) to older adults with MCI for 12 months. They identified increased TCv, as well as hippocampal volume, relative to placebo.

The above studies suggest that increasing the intake of n-3-FA may benefit cerebral structural integrity in older adults without dementia. Subsequently, we would anticipate that elevated dietary intake of fatty acids, or foods rich in these lipids, would have an impact upon cognitive function in this cohort. Increased fish consumption (which facilitates elevated blood and tissue n-3-FA concentrations) has been positively correlated with cognitive functioning as well as a reduced risk of dementia with age(200–204). Likewise, greater n-3-FA status appears to predict better executive functioning(190) as well as a lowered risk of cognitive decline(205). Conversely, a poorer intake of n-3-FA (particularly DHA) appears to predict an increased risk of developing dementia and poor cognitive performance(195,203). Similarly, concentrations of n-6-FA have been observed to be higher in older adults demonstrating cognitive decline than those with stable cognitive function over time(205). Likewise, a higher n-6-FA:n-3-FA ratio, reflecting greater n-6-FA consumption relative to n-3-FA, appears to predict an elevated risk of dementia(206).

Polyphenols

Polyphenols are naturally occurring compounds characterised by several hydroxyl groups on aromatic rings(207). They are present in the seeds, root, stem, leaf and fruit portions of many different plants and are commonly consumed within the human diet(208). Based upon their chemical structure, polyphenols are typically organised into two main groups: flavonoids and non-flavonoids(207). The flavonoid class (including flavonols, flavanones, flavones and anthocyanins) are perhaps the most widely studied class of polyphenol regarding potential therapeutic effects upon neurocognitive health and may be sourced from foods such as red grapes, blueberries, cocoa, green tea, citrus fruits and assorted vegetables (for example, onions, leeks, broccoli and celery)(209). Non-flavonoids include the stilbenes, of which resveratrol has been investigated as a potential modifier of neurocognitive health(210–212). Resveratrol is concentrated within the skin of red grapes, groundnuts, blueberries, raspberries and Japanese knotweed(208).

Increased consumption of foods or beverages rich in polyphenols such as chocolate, berries, tea, wine or grape juice appears to benefit cognitive performance in older adults(213–219). Likewise, oral supplementation with resveratrol has been shown to benefit cognitive function in rodents(220), as well as in human subjects aged 50–75 years(210). However, similar to other nutrients discussed in the present paper, there have been relatively few studies examining whether polyphenol supplementation benefits cerebral structural integrity in older adults without dementia.

There are a limited number of RCT that have investigated the effects of chronic resveratrol supplementation on cerebral structural integrity in dementia-free older adults. Witte et al. (210) examined hippocampal macro- and microstructural integrity in a sample of forty-six healthy middle-aged and older adults following chronic resveratrol supplementation (200 mg/d; derived from Japenese knotweed). While Witte et al. (210) identified improved verbal episodic memory performance following resveratrol treatment, no beneficial effects were identified for hippocampal structure. Hunh et al. (211) and Köbe et al. (212) also failed to identify significant benefits to hippocampal structure following resveratrol supplementation (dosage and treatment period were identical to that reported by Witte et al. (210)) in either healthy older adults or those diagnosed with MCI. However, Köbe et al. (212) do report a trend (though non-significant) towards moderate preservation of left anterior hippocampal volume following resveratrol treatment.

There are a number of factors that may explain the absence of significant treatment effects on cerebral structure in the aforementioned RCT. First, in each of these RCT, analysis was restricted to the hippocampus. Beneficial effects may have been apparent if analysis had been expanded to include additional regions known to deteriorate with age. Further, Witte et al. (210) and Huhn et al. (211) recognise the inclusion of healthy older adults and limited intervention period may have prevented identification of benefits to hippocampal structure, as this cohort may not demonstrate markedly reduced cerebral structure in such a short follow-up period. Köbe et al. (212) also failed to identify significant effects upon hippocampal structure despite their inclusion of older adults more susceptible to cerebral deterioration, though they did report a trend towards preservation of hippocampal volume following resveratrol treatment. It is also possible that the small sample sizes may have underpowered the studies for detecting beneficial effects to hippocampal structure (for example, power analysis by Huhn et al. (211) was based upon detecting cognitive effects rather than cerebral effects). Future research investigating resveratrol supplementation as a means of supporting cerebral structure in older adults should consider each of these points.

Despite the available studies on polyphenol supplementation indicating no beneficial effects on cerebral structure, it is still plausible that polyphenol supplementation may be neuroprotective. For example, biochemical and biophysical factors such as elevated concentrations of pro-inflammatory messengers(150,221,222) or reactive oxygen species(223–225), as well as poorer cardiovascular function as indicated by elevated blood pressure/hypertension(226–228) or increased arterial stiffness(229–231), are negatively related to cerebral structural integrity in older adults. However, the consumption of polyphenols such as flavonoids appears to promote anti-inflammatory(232) and antioxidant(233) effects, as well as better cardiovascular outcomes such as improved blood pressures/risk of hypertension(234,235) and reduced arterial stiffness(236). Increased ingestion of resveratrol likewise appears to exert both anti-inflammatory(237,238) and antioxidant effects(238,239), while also facilitating improvements in cardiovascular function such as reduced systolic blood pressure if given in high enough doses(240,241). As such, it is possible that polyphenol supplementation will exert beneficial effects upon cerebral structure if administered in high enough doses and over longer time periods (perhaps 1 year or more) but also in larger samples of older adults who are also at increased risk of cerebral (and cognitive) decline (for example, MCI or AAMI).

Vitamin D

Vitamin D is somewhat different from those nutrients outlined earlier in that it is obtained through direct exposure of skin to sunlight, in addition to dietary intake. However, despite the availability of vitamin D from sunlight exposure, vitamin D deficiency, or insufficiency, is quite common across the world(242,243). Global variations in vitamin D status may be due in part to biological factors such as skin pigmentation, though regional (for example, seasonal variation in light/dark cycles), cultural (for example, adoption of conservative clothing styles) and lifestyle factors (prevalence of indoor employment and leisure or poorer mobility)(242,243) limiting exposure to direct sunlight are also probably involved. For those individuals at risk of limited sunlight exposure, the importance of nutritionally sourced vitamin D becomes paramount. Several different food sources of vitamin D include animal liver, oily fish, egg yolk and shitake mushrooms. Vitamin D is also available from fortified cereals and milk, as well as singular or polynutrient supplements(244).

Regardless of how it is obtained, vitamin D undergoes hydroxylation within the liver, after which it enters circulation as 25-hydroxyvitamin D (25(OH)D)(242). Further modification occurs within the kidneys, whereby 25(OH)D is transformed into 1,25-dihydroxyvitamin D (1,25(OH)2D). Although this later form is the biologically active form of vitamin D which interacts with vitamin D receptors distributed throughout the body, many health effects are better correlated with the 25(OH)D variant(242).

Ensuring optimal vitamin D status may be an important factor for maintaining cerebral health. In older adults without dementia, increased concentrations of amyloid-β as well as proinflammatory messengers have been correlated with poorer cerebral structural integrity, especially WM integrity(150,221,222,245–249). However, increased intake of vitamin D (by diet or injection) appears to facilitate amyloid-β clearance(250–253), as well as elevating anti-inflammatory and lowering pro-inflammatory messengers(250,253–256). Subsequently, we would expect that in vivo concentrations of vitamin D would be correlated with cerebral structure integrity in older adults.

A positive relationship between vitamin D concentrations and cerebral structural integrity has been demonstrated using data from the Gait and Alzheimer Interactions Tracking (GAIT) study. Data from the GAIT study indicate that lower serum 25(OH)D is predictive of increased severity of WM abnormalities(257,258) as well as increased volume of the lateral ventricles, a marker of cerebral atrophy(259) in adults aged 60 years and over. It is important to note that these analyses of GAIT study data do not report excluding adults with dementia; in fact, inclusion criteria allowed MMSE scores to be as low as 10. Similar observations have been made in older adults aged 50–69 years (no cognitive screening is reported) with lower serum 25(OH)D concentrations correlating with greater WMH volume(260).

In addition to WM macrostructure, vitamin D status is also related to cerebral microstructure. In a study of older adults with memory impairment (adults reported subjective memory complaints, though some were identified as having amnestic MCI or probable Alzheimer’s disease), Moon et al. (261) compared the cerebral microstructure of adults with the lowest (n 28) in vivo concentrations of 25(OH)D with those with the highest (n 27) concentrations (mean concentrations 7·89 (sd 1·96) and 22·10 (sd 7·09) ng/ml, respectively). In contrast to adults with the highest concentrations of 25(OH)D, those with the lowest concentrations demonstrated reduced FA in a range of WM regions and tracts. These included the frontal interhemispheric association fibres of the superior and inferior longitudinal fasciculi, the anterior regions of the cingulum bundle, genu of the corpus callosum, as well as projection fibres of the corticospinal tracts, anterior limb of the internal capsule and anterior corona radiata.

It appears that very few studies have investigated the association between vitamin D and cerebral structural integrity in older adults deemed to be without dementia (following cognitive screening). Walhovd et al. (188) examined CT changes across the lifespan in a sample of 281 cognitively normal adults (aged 44–86 years), identifying that higher baseline concentrations of 25(OH)D predicted reduced thinning of right lateral prefrontal cortex over 2 years of follow-up. Likewise, a recent analysis of Framingham Heart Study data determined that vitamin D deficiency, defined as a serum 25(OH)D level below 10 ng/ml, was associated with lower hippocampal volume in middle-aged and older adults(262). Collectively, data from the above studies indicate that elevated vitamin D status may predict greater cerebral integrity in older adults.

With an apparent beneficial relationship between vitamin D and cerebral structural integrity, it follows that vitamin D is correlated with cognitive function. In a recent systematic review(263) low vitamin D status was associated with poorer cognitive performance and an increased frequency of dementia across six prospective studies consisting of adults aged 65 years or older (n 10896). In other analyses, lower vitamin D status was predictive of poorer cognitive performance, increased rate of cognitive decline, as well as an increased risk of developing MCI or dementia(264–266).

Overall, increased skin exposure to direct sunlight or increased consumption of foods rich in vitamin D may boost vitamin D status, thereby benefiting cerebral structural integrity in older adults. These effects may subsequently underpin the cognitive benefits associated with increased vitamin D status. However, the above studies are cross-sectional and may have included those demonstrating dementia symptomology, even if symptoms were only mild. Well-designed, long-duration RCT are required to determine whether increasing the levels of this vitamin through dietary modification (as opposed to that from increased sunlight exposure) is beneficial to cerebral structural integrity in older adults without dementia.

Patterns of nutritional intake

The above studies indicate that increased intake (inferred by FFQ or blood biomarker concentrations) of select nutrients may be beneficial to cerebral structure integrity in older adults. However, examining nutrients in isolation is not an accurate reflection of normal dietary intake, as diets are composed of complex combinations of nutrients. To this extent, several different studies have examined specific patterns or combinations of nutrients and how they relate to cerebral structural integrity in older adults.

In a study involving FFQ and MRI data from fifty-two cognitively normal adults aged 25–72 years, Berti et al. (267) performed principal components analysis in order to determine whether different nutrient patterns (NP) were associated with cerebral structural integrity. Overall, five distinct NP were identified, though only three were associated with cerebral structure across the entire sample. NP-1, comprised of B vitamins (B1, B2, B3, B6 and B9) and several minerals (i.e. Ca, Fe, Mg, P, K and Se), was positively correlated with frontal lobe GM volume. NP-4 (comprised of vitamin B12, vitamin D and Zn) was positively associated with frontal and temporal GM volumes, and negatively correlated with amyloid-β concentrations within the frontal and parietal lobes. Increased consumption of saturated or trans-saturated fats, cholesterol and Na (NP-5) was found to predict poorer GM volumes within frontal and limbic lobes, thereby demonstrating that while nutritional intake may benefit cerebral structure it may also facilitate detrimental effects.

One difficulty with interpreting the results outlined by Berti et al. (267) is that their analysis involved a small sample of participants across a large non-specific age range (i.e. 25–72 years). As such, the results of this study suggest a relationship between nutritional intake and cerebral structure in adults more broadly. However, Bowman et al. (268) examined thirty separate blood biomarkers associated with a range of different nutrients in a sample of 293 adults aged 65 years and older. The authors performed principal components analysis, determining the presence of eight separate nutrient biomarker patterns (NBP). Of these biomarker patterns, NBP-1 (associated with vitamins B1, B2, B6, B12, folate, as well as vitamins C, D and E) predicted greater TCv whereas NBP-8 (associated with trans-saturated fat) was inversely related to TCv. Bowman et al. (268) also observed that NBP-5 (associated with intake of n-3-FA) was inversely associated with WMH volume. Moreover, NBP-1 (vitamins B, C, D and E), NBP-5 (n-3-FA including EPA and DHA), NBP-6 (n-6-FA including arachidonic acid and γ-linolenic acid), NBP-7 (HDL-cholesterol, lutein and uric acid) and finally NBP-8 (trans-saturated fat) were found to correlate with cognitive performance. Specially, better performance in domains such as executive processing, attention and visuospatial functioning were positively associated with NBP-1, -5 and -7, while worse performance in domains such as memory, attentional, language and processing speed were associated with NBP-6 and -8.

In another study, Gu et al. (269) administered a sixty-one-item FFQ to 239 adults (aged 65 years or older) who also underwent diffusion MRI. Gu et al. (269) performed principal component analysis on the FFQ data, identifying six separate NP. Interestingly, only NP-6, composed of n-3 and n-6 PUFA as well as vitamin E, was significantly associated with cerebral microstructural integrity in these adults (specifically the DTI metric FA). Older adults whose NP-6 score was in the highest tertile demonstrated greater FA than those in the middle or lowest tertiles. Importantly, Gu et al. (269) observed that only n-3-FA and vitamin E levels were positively associated with cerebral FA values. In secondary analysis with only 211 dementia-free adults, both NP-6 and n-3-FA remained associated with WM microstructure. Moreover, they demonstrated that cerebral FA scores completely mediated the relationship between NP-6 and cognitive performance.

Adherence to Mediterranean, ‘prudent’ or Western-style diets

In addition to those key nutrients discussed earlier, a number of studies have examined the extent to which adherence to prudent diets such as a MeDI predicts cerebral structural integrity. A MeDI prescribes a high consumption of fruit, vegetables, legumes, whole grains and olive oil, moderate ingestion of fish, low-moderate intake of red wine with meals and low-fat dairy products (primarily as yoghurt and cheese) but also infrequent consumption of animal products (i.e. red meat and milk)(270,271). Likewise, the Mediterranean-DASH (Dietary Approaches to Stop Hypertension) Intervention for Neurodegenerative Delay, or MIND, diet recommends increased intake of fruit, vegetables, grains and fish, moderate intake of low-fat or non-fat dairy products, and low consumption of meat(272). Due to the foods prescribed, greater adherence to either of these diets would ensure heightened ingestion of many of the nutrients already discussed within the present review.

Prudent dietary patterns such as a MeDI and the MIND appear to benefit cognitive functioning when adherence to these diets is increased. A recent systematic review identified that greater adherence to the MeDI appears to facilitate a reduced rate of cognitive decline with age, as well as reduced risk of developing conditions such as MCI or Alzheimer’s disease(273). Greater adherence to a MeDI has also been positively related to working memory and executive performance in middle-aged and older adults(270). The MIND diet has also been related to reduced rate of age-related cognitive decline(274) and risk of developing Alzheimer’s disease(272).

Probably underpinning the apparent cognitive benefits associated with these diets are benefits to cerebral structural integrity. In fact, several studies have observed greater MeDI adherence predicting greater TCv as well as regional GM and WM volumes in addition to elevated CT within frontal, parietal, temporal and occipital zones(275–277). Similarly, Pelletier et al. (278) observed that greater adherence to a MeDI was associated with greater cerebral microstructural integrity after 9 years of follow-up in older adults within the Bordeaux Three-City Study (aged 67–83 years). This was evident as lower MD, RD and AxD scores within WM regions including the corpus callosum, anterior and posterior thalamic radiations, the paracingulate gyrus, cingulum and the parahippocampal fornix. Importantly, Pelletier et al. (278) identified that preserved integrity within the before-mentioned regions was associated with higher cognitive performance.

Though limited, there are also longitudinal data indicating that adherence to a MeDI is beneficial to cerebral structural integrity in older adults. Luciano et al. (279) examined FFQ data derived from approximately 562 healthy older adults of the Lothian Birth Cohort, aged in their early seventies. The extent to which participants adhered to a MeDI was determined at baseline, while MRI was performed 3 and 6 years later, when participants were aged 73 and 76 years, respectively. Luciano et al. (279) observed that a lower MeDI score predicted greater change in TCv over 3 years, even after adjusting for relevant covariates including cognitive impairment during follow-up (indicated by MMSE score).

There are also data correlating specific component scores within a MeDI (or whole foods consistent with MeDI components) with cerebral structural integrity. More frequent fish intake, greater consumption of vegetables, legumes and whole grains, lower consumption of meat/meat products or improved ratio of monounsaturated:saturated fat consumption have been correlated with greater TCv, CT and reduced WMH volumes(184,271,276,277,280). Pelletier et al. (278) observed greater dairy product intake predicting elevated RD and lower FA within the body and genu of the corpus callosum, while moderate alcohol intake (as opposed to abstinence or intensive alcohol consumption) was associated with better microstructural integrity within the same regions associated with dairy product intake. Other studies have observed increased alcohol intake being either beneficial(281–283) or detrimental(284–286) to cerebral structural integrity. However, only Gu et al. (287) appears to have differentiated between alcohol sources (wine, beer or liquor). Importantly, Gu et al. (287) observed that only low to moderate wine consumption was associated with greater TCv compared with no alcohol consumption. Differentiating alcohol sources provides greater accuracy when examining alcohol intake in the context of a MeDI, as this diet prescribes low-to-moderate consumption of red wine (not alcohol in general), due to it being a rich source of polyphenols from red grapes. As such, future work determining whether moderate alcohol consumption, in the context of a MeDI, is beneficial to cerebral structure, should specifically examine wine consumption rather than total alcohol intake.

Another diet, markedly different from a MeDI, is what may be considered a WeDI. A WeDI is typically characterised by high consumption of processed sugars, saturated and trans-saturated fats in addition to Na (salt), but also reduced consumption of fruit and vegetables. In one recent study, Jacka et al. (288) observed that in adults aged 60–64 years, greater adherence to a WeDI predicted smaller hippocampal volume. Conversely, greater adherence to a healthier ‘prudent’ diet (consisting of fresh vegetables, salad, fruit and grilled fish) was associated with larger hippocampal volumes. However, adherence to either diet was not observed to differentially predict hippocampal volume change over 4 years of follow-up. Other work already discussed has indicted that greater intake of trans-saturated fat appears to predict poorer TCv(268) while elevated intake of trans-saturated fat, cholesterol and Na appeared to correlate with reduced GM volumes within frontal and limbic regions in adults aged 25–72 years(267).

More recently, Croll et al. (289) examined the extent to which diet quality was correlated with cerebral structure in a large cohort (n 4213) of dementia-free Dutch adults (mean age 65·7 years). Diet was assessed using an FFQ, with diet quality being determined via level of adherence to official Dutch dietary guidelines (adherence was scored for fourteen items, with overall adherence/diet quality score ranging from 0 to 14). MeDI adherence score was also calculated to allow comparisons with other studies. After adjusting for covariates including age, sex, physical activity, BMI and energy intake, Croll et al. (289) observed that higher dietary quality score (i.e. greater adherence to Dutch dietary guidelines) correlated with larger TCV, greater GM and WM volumes, as well as increased hippocampal volume. Moreover, Croll et al. (289) identified that these effects were associated with intake of a number of food items specified by the guidelines including vegetables, fruit, whole grains, nuts, dairy products, fish, as well as lower intake of sugar-rich beverages. Similar effects were also apparent with increased MeDI adherence. These results build upon those discussed earlier whereby a more ‘prudent’ diet predicts greater cerebral structural integrity in older adults.

On the whole, greater adherence to a ‘prudent’ diet such as a MeDI, as opposed to a WeDI, may facilitate greater cerebral structural integrity in older adults. However, it is important to note that these studies are generally cross-sectional or prospective by design. As such, they cannot infer causality. Ideally, clinical trials whereby participants were prescribed a MeDI (but also comparison diets such as the WeDI or an unchanged diet as a control group) whilst also undergoing pre- and post-intervention structural or diffusion MRI scans would provide greater insight into the potential neuroprotective effects of this diet. However, to date no such trial appears to have been performed.

Limitations and future directions

There is a growing literature indicating that increased intake of select nutrients (inferred by FFQ or blood biomarker concentrations) is associated with cerebral structural integrity in older adults without dementia. However, there are a number of important limitations with the present research that should be considered. One limitation is that the majority of data comes from cross-sectional studies, which cannot infer causality. Moreover, the cross-sectional literature often utilises poorly defined participant samples (for example, ‘dementia free’) using very basic screening measures (for example, MMSE) rather than specific classifications for neurocognitive health (for example, cognitively normal, AAMI or MCI). As indicated earlier, there are differences in cerebral structural integrity between cognitively normal adults and those with conditions such as AAMI or MCI. As such, the association between nutritional intake and cerebral structural integrity may differ between these groups. Likewise, the cross-sectional studies discussed within the present review often report a lengthy delay (sometimes as much as 8 years) between initial nutrient assessment (FFQ or blood draw/biomarker assessment) and MRI. During this time, it is possible that participants changed their diets, thereby confounding the association between nutritional intake and cerebral structure, or developed more severe neurocognitive impairment. Further, when investigating whole diets such as the MeDI, studies have often taken a much more inclusive approach to diet-specific food groups. This is particularly pertinent regarding alcohol intake, with many studies investigating total alcohol consumption while the MeDI specifically focuses on red wine consumption. Moreover, many of these MeDI studies do not examine alternative diets for comparison of effects.

The available RCT typically address the aforementioned issues through use of specific participant samples (for example, MCI) as well as specifying the length of time between MRI measurements. Importantly, RCT also allow causality to be inferred. However, due to cost restraints, RCT often involve small participant samples, potentially underpowering analysis for detecting cerebral effects. Some have also restricted their analysis to highly specific cerebral regions (for example, hippocampus), whilst a more inclusive approach may have allowed benefits to be observed. Future cross-sectional analyses and RCT investigating the association between nutritional intake and cerebral structural integrity should address these methodological issues in order to improve our understanding of the neurocognitive effects associated with nutritional intake.

Summary and conclusion

The human cerebrum undergoes marked deterioration with increasing age, typically between midlife to older adulthood. Declining cerebral structural integrity appears to be a strong predictor of cognitive function in older adults. Further, it appears that conditions such as AAMI or MCI are characterised by more severe cerebral deterioration than that observed during normal ageing.

There is a growing, though currently limited, literature suggesting that increased intake (inferred by FFQ or blood biomarker concentrations) of select nutrients (predominantly vitamins B6, B12, folate, choline, n-3-FA and vitamin D) or adherence to prudent diets (for example, MeDI) supports cerebral structure in older adults without dementia. There is also a growing number of RCT indicating that nutritional supplementation, particularly B vitamins (for example, B6, B12 and folic acid) or n-3-FA may be neuroprotective. However, these studies do contain a number of important limitations discussed earlier, which should be addressed in future work.

Overall, the available literature suggests that elevated ingestion of select key nutrients, or greater adherence to specific diets (for example, the MeDI), may benefit cerebral structural integrity in older adults. Some studies have even indicated that cerebral structural integrity may mediate the relationship between nutritional intake and cognitive function. As such, nutritional modification may be a readily implementable therapeutic intervention, capable of supporting neurocognitive health with age. If these effects can be confirmed in larger, well-designed RCT, community attitudes regarding long-term dietary behaviours may begin to change. Not only would this contribute to maximising our own neurocognitive health as we age, but society as a whole may benefit from lower incidence of age-related neurodegenerative diseases such as dementia.

Acknowledgements

J. M. R. drafted the manuscript. All authors were actively involved in the planning and the development of the manuscript. J. M. R. receives a Research Training Program Stipend as part of his postgraduate studies. J. M. R. declares no potential conflicts of interest.

H. M. has received research funding from the National Health and Medical Research Council, Australian Research Council, Alzheimer Australia grants as well as from Swisse Wellness.

D. J. W. has received research funding and/or consultancy/speaker fees from Abbott Nutrition, Arla Foods, Bayer Healthcare and Neurobrands.

A. S. has received research funding and/or consultancy/speaker fees from a number of food industry partners including Abbott Nutrition, Arla Foods, Australian Wine Research Institute, Barilla, Bayer Healthcare, Blackmores, Cognis, Cyvex, Dairy Health Innovation Consortium, Danone, Ginsana, GlaxoSmithKline Healthcare, Masterfoods, Martek, Naturex, Nestlé, Novartis, Red Bull, Sanofi, Unilever, Verdure Sciences and Wrigley.

A. P. has received research funding and/or consultancy/speaker fees from Biostime, Blackmores, DSM, LifeVantage, Novasel Australia, Enzo Nutraceuticals and Swisse Wellness. A. P. was previously a member of the Scientific Advisory Panel for Swisse Wellness.

The present study was not supported by any specific grant from any funding agency, commercial or not-for-profit entity.

Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/S0954422418000185

References

1. United Nations, Department of Economic and Social Affairs, Population Division (2015) World Population Ageing 2015. New York: United Nations.Google Scholar
2. Davis, SW, Dennis, NA, Buchler, NG, et al. (2009) Assessing the effects of age on long white matter tracts using diffusion tensor tractography. NeuroImage 46, 530541.CrossRefGoogle Scholar
3. Bendlin, BB, Fitzgerald, ME, Ries, ML, et al. (2010) White matter in aging and cognition: a cross-sectional study of microstructure in adults aged eighteen to eighty-three. Dev Neuropsychol 35, 257277.CrossRefGoogle ScholarPubMed
4. Gunning-Dixon, FM & Raz, N (2003) Neuroanatomical correlates of selected executive functions in middle-aged and older adults: a prospective MRI study. Neuropsychologia 41, 19291941.CrossRefGoogle ScholarPubMed
5. Fleischman, DA, Leurgans, S, Arfanakis, K, et al. (2014) Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. Brain Struct Funct 219, 20292049.CrossRefGoogle ScholarPubMed
6. Prins, ND & Scheltens, P (2015) White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 11, 157165.CrossRefGoogle ScholarPubMed
7. Papp, K V, Kaplan, RF, Springate, B, et al. (2014) Processing speed in normal aging: effects of white matter hyperintensities and hippocampal volume loss. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 21, 197213.CrossRefGoogle ScholarPubMed
8. Bennett, IJ & Madden, DJ (2014) Disconnected aging: cerebral white matter integrity and age-related differences in cognition. Neuroscience 276, 187205.CrossRefGoogle ScholarPubMed
9. Song, S-K, Sun, S-W, Ju, W-K, et al. (2003) Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. NeuroImage 20, 17141722.CrossRefGoogle ScholarPubMed
10. Sun, S-W, Liang, H-F, Trinkaus, K, et al. (2006) Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 55, 302308.CrossRefGoogle ScholarPubMed
11. Sun, S-W, Liang, H-F, Le, TQ, et al. (2006) Differential sensitivity of in vivo and ex vivo diffusion tensor imaging to evolving optic nerve injury in mice with retinal ischemia. NeuroImage 32, 11951204.CrossRefGoogle ScholarPubMed
12. Song, S-K, Sun, S-W, Ramsbottom, MJ, et al. (2002) Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. NeuroImage 17, 14291436.CrossRefGoogle Scholar
13. Song, S-K, Yoshino, J, Le, TQ, et al. (2005) Demyelination increases radial diffusivity in corpus callosum of mouse brain. NeuroImage 26, 132140.CrossRefGoogle ScholarPubMed
14. Resnick, SM, Goldszal, AF, Davatzikos, C, et al. (2000) One-year age changes in MRI brain volumes in older adults. Cereb Cortex 10, 464472.CrossRefGoogle ScholarPubMed
15. Courchesne, E, Chisum, HJ, Townsend, J, et al. (2000) Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Neuroradiology 216, 672682.Google ScholarPubMed
16. Fotenos, A, Snyder, A, Girton, LE, et al. (2005) Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 64, 10321039.CrossRefGoogle ScholarPubMed
17. Raz, N, Gunning, FM, Head, D, et al. (1997) Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex 7, 268282.CrossRefGoogle ScholarPubMed
18. Resnick, SM, Pham, DL, Kraut, MA, et al. (2003) Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 23, 32953301.CrossRefGoogle ScholarPubMed
19. Gattringer, T, Enzinger, C, Ropele, S, et al. (2011) Vascular risk factors, white matter hyperintensities and hippocampal volume in normal elderly individuals. Dement Geriatr Cogn Disord 33, 2934.CrossRefGoogle Scholar
20. Enzinger, C, Fazekas, F, Matthews, PM, et al. (2005) Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 64, 17041711.CrossRefGoogle ScholarPubMed
21. Scahill, RI, Frist, C, Jenkins, R, et al. (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60, 989994.CrossRefGoogle ScholarPubMed
22. Allen, JS, Bruss, J, Brown, CK, et al. (2005) Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region. Neurobiol Aging 26, 12451260.CrossRefGoogle Scholar
23. Bartzokis, G, Beckson, M, Lu, PH, et al. (2001) Age-related changes in frontal and temporal lobe volumes in men. Arch Gen Psychiatry 58, 461465.CrossRefGoogle ScholarPubMed
24. Jernigan, TL, Archibald, SL, Fennema-Notestine, C, et al. (2001) Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging 22, 581594.CrossRefGoogle ScholarPubMed
25. McDonald, CR, McEvoy, LK, Gharapetian, L, et al. (2009) Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 73, 457465.CrossRefGoogle ScholarPubMed
26. Good, CD, Johnsrude, IS, Ashburner, J, et al. (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14, 2136.CrossRefGoogle ScholarPubMed
27. Paul, R, Grieve, SM, Chaudary, B, et al. (2009) Relative contributions of the cerebellar vermis and prefrontal lobe volumes on cognitive function across the adult lifespan. Neurobiol Aging 30, 457465.CrossRefGoogle ScholarPubMed
28. Smith, CD, Chebrolu, H, Wekstein, DR, et al. (2007) Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging 28, 10751087.CrossRefGoogle ScholarPubMed
29. Tisserand, DJ, van Boxtel, MPJ, Pruessner, JC, et al. (2004) A voxel-based morphometric study to determine individual differences in gray matter density associated with age and cognitive change over time. Cereb Cortex 14, 966973.CrossRefGoogle ScholarPubMed
30. Curiati, PK, Tamashiro, JH, Squarzoni, P, et al. (2009) Brain structural variability due to aging and gender in cognitively healthy elders: results from the Sao Paulo Ageing and Health Study. Am J Neuroradiol 30, 18501856.CrossRefGoogle Scholar
31. Sowell, ER, Peterson, BS, Thompson, PM, et al. (2003) Mapping cortical change across the human life span. Nat Neurosci 6, 309315.CrossRefGoogle ScholarPubMed
32. Driscoll, I, Davatzikos, C, An, Y, et al. (2009) Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 72, 19061913.CrossRefGoogle ScholarPubMed
33. Fjell, AM, Walhovd, KB, Fennema-Notestine, C, et al. (2009) One-year brain atrophy evident in healthy aging. J Neurosci 29, 1522315231.CrossRefGoogle ScholarPubMed
34. Giorgio, A, Santelli, L, Tomassini, V, et al. (2010) Age-related changes in grey and white matter structure throughout adulthood. NeuroImage 51, 943951.CrossRefGoogle ScholarPubMed
35. Hogstrom, LJ, Westlye, LT, Walhovd, KB, et al. (2013) The structure of the cerebral cortex across adult life: age-related patterns of surface area, thickness, and gyrification. Cereb Cortex 23, 25212530.CrossRefGoogle ScholarPubMed
36. Raz, N, Gunning-Dixon, FM, Head, D, et al. (1998) Neuroanatomical correlates of cognitive aging: evidence from structural magnetic resonance imaging. Neuropsychology 12, 95114.CrossRefGoogle ScholarPubMed
37. Raz, N, Lindenberger, U, Rodrigue, KM, et al. (2005) Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 15, 16761689.CrossRefGoogle ScholarPubMed
38. Salat, DH, Buckner, RL, Snyder, AZ, et al. (2004) Thinning of the cerebral cortex in aging. Cereb Cortex 14, 721730.CrossRefGoogle Scholar
39. Schuff, N, Tosun, D, Insel, PS, et al. (2012) Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging 33, 845855.CrossRefGoogle ScholarPubMed
40. Taki, Y, Thyreau, B, Kinomura, S, et al. (2013) A longitudinal study of age- and gender-related annual rate of volume changes in regional gray matter in healthy adults. Hum Brain Mapp 34, 22922301.CrossRefGoogle ScholarPubMed
41. Ziegler, G, Dahnke, R, Jäncke, L, et al. (2012) Brain structural trajectories over the adult lifespan. Hum Brain Mapp 33, 23772389.CrossRefGoogle ScholarPubMed
42. Zimmerman, M, Brickman, A, Paul, R, et al. (2006) The relationship between frontal gray matter volume and cognition varies across the healthy adult lifespan. Am J Geriatr Psychiatry 14, 823833.CrossRefGoogle ScholarPubMed
43. Du, AT, Schuff, N, Zhu, XP, et al. (2003) Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 60, 481486.CrossRefGoogle ScholarPubMed
44. Jack, CR, Petersen, RC, Xu, Y, et al. (1998) Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology 51, 993999.CrossRefGoogle ScholarPubMed
45. Walhovd, KB, Fjell, AM, Reinvang, I, et al. (2005) Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiol Aging 26, 12611270.CrossRefGoogle ScholarPubMed
46. Walhovd, KB, Westlye, LT, Amlien, I, et al. (2011) Consistent neuroanatomical age-related volume differences across multiple samples. Neurobiol Aging 32, 916932.CrossRefGoogle ScholarPubMed
47. Westlye, LT, Walhovd, KB, Dale, AM, et al. (2010) Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. Cereb Cortex 20, 20552068.CrossRefGoogle ScholarPubMed
48. Habes, M, Erus, G, Toledo, JB, et al. (2016) White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain 139, 11641179.CrossRefGoogle ScholarPubMed
49. Lockhart, SN, Mayda, AB, Roach, AE, et al. (2012) Episodic memory function is associated with multiple measures of white matter integrity in cognitive aging. Front Hum Neurosci 6, 56.CrossRefGoogle ScholarPubMed
50. Raz, N, Yang, YQ, Rodrigue, KM, et al. (2012) White matter deterioration in 15 months: latent growth curve models in healthy adults. Neurobiol Aging 33, 429.e1429.e5.CrossRefGoogle ScholarPubMed
51. Vannorsdall, TD, Waldstein, SR, Kraut, M, et al. (2009) White matter abnormalities and cognition in a community sample. Arch Clin Neuropsychol 24, 209217.CrossRefGoogle Scholar
52. Abe, O, Aoki, S, Hayashi, N, et al. (2002) Normal aging in the central nervous system: quantitative MR diffusion-tensor analysis. Neurobiol Aging 23, 433441.CrossRefGoogle ScholarPubMed
53. Barrick, TR, Charlton, RA, Clark, CA, et al. (2010) White matter structural decline in normal ageing: a prospective longitudinal study using tract-based spatial statistics. NeuroImage 51, 565577.CrossRefGoogle ScholarPubMed
54. Bennett, IJ, Madden, DJ, Vaidya, CJ, et al. (2010) Age-related differences in multiple measures of white matter integrity: a diffusion tensor imaging study of healthy aging. Hum Brain Mapp 31, 378390.Google ScholarPubMed
55. Burzynska, A, Preuschhof, C, Bäckman, L, et al. (2010) Age-related differences in white matter microstructure: region-specific patterns of diffusivity. NeuroImage 49, 21042112.CrossRefGoogle ScholarPubMed
56. Charlton, RA, Barrick, TR, McIntyre, DJ, et al. (2006) White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology 66, 217222.CrossRefGoogle ScholarPubMed
57. Hsu, J-L, Van Hecke, W, Bai, C-H, et al. (2010) Microstructural white matter changes in normal aging: a diffusion tensor imaging study with higher-order polynomial regression models. NeuroImage 49, 3243.CrossRefGoogle ScholarPubMed
58. Inano, S, Takao, H, Hayashi, N, et al. (2011) Effects of age and gender on white matter. Am J Neuroradiol 32, 21032109.CrossRefGoogle ScholarPubMed
59. Madden, DJ, Whiting, WL, Huettel, SA, et al. (2004) Diffusion tensor imaging of adult age differences in cerebral white matter: relation to response time. NeuroImage 21, 11741181.CrossRefGoogle ScholarPubMed
60. Madden, DJ, Spaniol, J, Costello, MC, et al. (2008) Cerebral white matter integrity mediates adult age differences in cognitive performance. J Cogn Neurosci 21, 289302.CrossRefGoogle Scholar
61. Mella, N, de Ribaupierre, S, Eagleson, R, et al. (2013) Cognitive intraindividual variability and white matter integrity in aging. Sci World J 2013, 350623.CrossRefGoogle Scholar
62. Sala, S, Agosta, F, Pagani, E, et al. (2012) Microstructural changes and atrophy in brain white matter tracts with aging. Neurobiol Aging 33, 488498.CrossRefGoogle ScholarPubMed
63. Xiang, Z, Baoqing, L & Baoci, S (2014) Age related white matter degradation rule of normal human brain: the evidence from diffusion tensor magnetic resonance imaging. Chin Med J 127, 532537.Google Scholar
64. Borghesani, PR, Madhyastha, TM, Aylward, EH, et al. (2013) The association between higher order abilities, processing speed, and age are variably mediated by white matter integrity during typical aging. Neuropsychologia 51, 14351444.CrossRefGoogle ScholarPubMed
65. Brickman, AM, Meier, IB, Korgaonkar, MS, et al. (2012) Testing the white matter retrogenesis hypothesis of cognitive aging. Neurobiol Aging 33, 16991715.CrossRefGoogle ScholarPubMed
66. Charlton, RA, Barrick, TR, Lawes, INC, et al. (2010) White matter pathways associated with working memory in normal aging. Cortex 46, 474489.CrossRefGoogle ScholarPubMed
67. Kerchner, GA, Racine, CA, Hale, S, et al. (2012) Cognitive processing speed in older adults: relationship with white matter integrity. PLOS ONE 7, e50425.CrossRefGoogle ScholarPubMed
68. Metzler-Baddeley, C, Jones, DK, Belaroussi, B, et al. (2011) Frontotemporal connections in episodic memory and aging: a diffusion MRI tractography study. J Neurosci 31, 1323613245.CrossRefGoogle ScholarPubMed
69. Salami, A, Eriksson, J, Nilsson, L-G, et al. (2012) Age-related white matter microstructural differences partly mediate age-related decline in processing speed but not cognition. Biochim Biophys Acta 1822, 408415.CrossRefGoogle Scholar
70. Yang, Y, Bender, AR & Raz, N (2015) Age related differences in reaction time components and diffusion properties of normal-appearing white matter in healthy adults. Neuropsychologia 66, 246258.CrossRefGoogle ScholarPubMed
71. Tabatabaei-Jafari, H, Shaw, ME & Cherbuin, N (2015) Cerebral atrophy in mild cognitive impairment: a systematic review with meta-analysis. Alzheimer’s Dement 1, 487504.Google ScholarPubMed
72. Sluimer, JD, van der Flier, WM, Karas, GB, et al. (2008) Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 248, 590598.CrossRefGoogle ScholarPubMed
73. Anstey, KJ & Maller, JJ (2003) The role of volumetric MRI in understanding mild cognitive impairment and similar classifications. Aging Ment Health 7, 238250.CrossRefGoogle ScholarPubMed
74. Barbeau, EJ, Ranjeva, JP, Didic, M, et al. (2008) Profile of memory impairment and gray matter loss in amnestic mild cognitive impairment. Neuropsychologia 46, 10091019.CrossRefGoogle ScholarPubMed
75. Dos Santos, V, Thomann, PA, Wüstenberg, T, et al. (2011) Morphological cerebral correlates of CERAD test performance in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 23, 411420.CrossRefGoogle ScholarPubMed
76. Elshafey, R, Hassanien, O, Khalil, M, et al. (2014) Hippocampus, caudate nucleus and entorhinal cortex volumetric MRI measurements in discrimination between Alzheimer’s disease, mild cognitive impairment, and normal aging. Egypt J Radiol Nucl Med 45, 511518.CrossRefGoogle Scholar
77. Fennema-Notestine, C, Hagler, DJ, McEvoy, LK, et al. (2009) Structural MRI biomarkers for preclinical and mild Alzheimer’s disease. Hum Brain Mapp 30, 32383253.CrossRefGoogle ScholarPubMed
78. Fujishima, M, Maikusa, N, Nakamura, K, et al. (2014) Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities. Front Aging Neurosci 6, 306.CrossRefGoogle ScholarPubMed
79. Hämäläinen, A, Tervo, S, Grau-Olivares, M, et al. (2007) Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. NeuroImage 37, 11221131.CrossRefGoogle ScholarPubMed
80. Hänggi, J, Streffer, J, Jäncke, L, et al. (2011) Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer’s disease. J Alzheimers Dis 26, 719734.CrossRefGoogle ScholarPubMed
81. McDonald, CR, Gharapetian, L, McEvoy, LK, et al. (2012) Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging 33, 242253.CrossRefGoogle ScholarPubMed
82. Zheng, D, Sun, H, Dong, X, et al. (2014) Executive dysfunction and gray matter atrophy in amnestic mild cognitive impairment. Neurobiol Aging 35, 548555.CrossRefGoogle ScholarPubMed
83. Smith, EE, Salat, DH, Jeng, J, et al. (2011) Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 76, 149211429.CrossRefGoogle ScholarPubMed
84. Maillard, P, Carmichael, O, Fletcher, E, et al. (2012) Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 79, 442448.CrossRefGoogle ScholarPubMed
85. Carmichael, O, Schwarz, C, Drucker, D, et al. (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer Disease Neuroimaging Initiative. Arch Neurol 67, 13701378.CrossRefGoogle ScholarPubMed
86. Naranjo, IC, Cuenca, JCP, de San Juan, BD, et al. (2015) Association of vascular factors and amnestic mild cognitive impairment: a comprehensive approach. J Alzheimers Dis 44, 695704.CrossRefGoogle Scholar
87. Bosch, B, Arenaza-Urquijo, EM, Rami, L, et al. (2012) Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol Aging 33, 6174.CrossRefGoogle Scholar
88. Cooley, SA, Cabeen, RP, Laidlaw, DH, et al. (2015) Posterior brain white matter abnormalities in older adults with probable mild cognitive impairment. J Clin Exp Neuropsychol 37, 6169.CrossRefGoogle ScholarPubMed
89. He, J, Wong, VSS, Fletcher, E, et al. (2012) The contributions of MRI-based measures of gray matter, white matter hyperintensity, and white matter integrity to late-life cognition. Am J Neuroradiol 33, 17971803.CrossRefGoogle ScholarPubMed
90. Liu, Y, Spulber, G, Lehtimäki, KK, et al. (2011) Diffusion tensor imaging and tract-based spatial statistics in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 32, 15581571.CrossRefGoogle ScholarPubMed
91. Rose, SE, McMahon, KL, Janke, AL, et al. (2006) Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment. J Neurol Neurosurg Psychiatry 77, 11221128.CrossRefGoogle ScholarPubMed
92. Sali, D, Dimitra, S, Verganelakis, DA, et al. (2013) Diffusion tensor imaging (DTI) in the detection of white matter lesions in patients with mild cognitive impairment (MCI). Acta Neurol Belg 113, 441451.CrossRefGoogle Scholar
93. Stricker, NH, Salat, DH, Foley, JM, et al. (2013) Decreased white matter integrity in neuropsychologically defined mild cognitive impairment is independent of cortical thinning. J Int Neuropsychol Soc 19, 925937.CrossRefGoogle ScholarPubMed
94. Stricker, NH, Salat, DH, Kuhn, TP, et al. (2016) Mild cognitive impairment is associated with white matter integrity changes in late-myelinating regions within the corpus callosum. Am J Alzheimers Dis Other Demen 31, 6875.CrossRefGoogle ScholarPubMed
95. Wang, P-N, Chou, K-H, Chang, N-J, et al. (2014) Callosal degeneration topographically correlated with cognitive function in amnestic mild cognitive impairment and Alzheimer’s disease dementia. Hum Brain Mapp 35, 15291543.CrossRefGoogle ScholarPubMed
96. Wang, Y, West, JD, Flashman, LA, et al. (2012) Selective changes in white matter integrity in MCI and older adults with cognitive complaints. Biochim Biophys Acta 1822, 423430.CrossRefGoogle ScholarPubMed
97. Zhang, Y, Schuff, N, Camacho, M, et al. (2013) MRI markers for mild cognitive impairment: comparisons between white matter integrity and gray matter volume measurements. PLOS ONE 8, e66367.CrossRefGoogle ScholarPubMed
98. Zhuang, L, Wen, W, Trollor, JN, et al. (2012) Abnormalities of the fornix in mild cognitive impairment are related to episodic memory loss. J Alzheimer’s Dis 29, 629639.CrossRefGoogle ScholarPubMed
99. Zhuang, L, Sachdev, PS, Trollor, JN, et al. (2013) Microstructural white matter changes, not hippocampal atrophy, detect early amnestic mild cognitive impairment. PLOS ONE 8, e58887.CrossRefGoogle Scholar
100. Boespflug, EL, Storrs, J, Sadat-Hossieny, S, et al. (2014) Full diffusion characterization implicates regionally disparate neuropathology in mild cognitive impairment. Brain Struct Funct 219, 367379.CrossRefGoogle ScholarPubMed
101. Arvanitakis, Z, Fleischman, DA, Arfanakis, K, et al. (2016) Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct 221, 21352146.CrossRefGoogle ScholarPubMed
102. Tuladhar, AM, Reid, AT, Shumskaya, E, et al. (2015) Relationship between white matter hyperintensities, cortical thickness, and cognition. Stroke 46, 425432.CrossRefGoogle ScholarPubMed
103. Schmidt-Wilcke, T, Poljansky, S, Hierlmeier, S, et al. (2009) Memory performance correlates with gray matter density in the ento-/perirhinal cortex and posterior hippocampus in patients with mild cognitive impairment and healthy controls – a voxel based morphometry study. NeuroImage 47, 19141920.CrossRefGoogle ScholarPubMed
104. Newman, LM, Trivedi, MA, Bendlin, BB, et al. (2007) The relationship between gray matter morphometry and neuropsychological performance in a large sample of cognitively healthy adults. Brain Imaging Behav 1, 310.CrossRefGoogle Scholar
105. Brickman, AM, Zimmerman, ME, Paul, RH, et al. (2006) Regional white matter and neuropsychological functioning across the adult lifespan. Biol Psychiatry 60, 444453.CrossRefGoogle ScholarPubMed
106. Cardenas, V, Chao, L, Studholme, C, et al. (2011) Brain atrophy associated with baseline and longitudinal measures of cognition. Neurobiol Aging 32, 572580.CrossRefGoogle ScholarPubMed
107. Meyer, P, Feldkamp, H, Hoppstädter, M, et al. (2013) Using voxel-based morphometry to examine the relationship between regional brain volumes and memory performance in amnestic mild cognitive impairment. Front Behav Neurosci 7, 89.CrossRefGoogle ScholarPubMed
108. Bombois, S, Debette, S, Delbeuck, X, et al. (2007) Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes. Stroke 38, 25952597.CrossRefGoogle ScholarPubMed
109. Gold, BT, Powell, DK, Xuan, L, et al. (2010) Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. Neurobiol Aging 31, 512522.CrossRefGoogle ScholarPubMed
110. Grambaite, R, Stenset, V, Reinvang, I, et al. (2010) White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels. J Int Neuropsychol Soc 16, 5869.CrossRefGoogle ScholarPubMed
111. Grieve, SM, Williams, LM, Paul, RH, et al. (2007) Cognitive aging, executive function, and fractional anisotrpy: a diffusion tensor MR imaging study. Am J Neuroradiol 28, 226235.Google Scholar
112. Jacobs, HIL, Leritz, EC, Williams, VJ, et al. (2013) Association between white matter microstructure, executive functions, and processing speed in older adults: the impact of vascular health. Hum Brain Mapp 34, 7795.CrossRefGoogle ScholarPubMed
113. Kennedy, KM & Raz, N (2009) Aging white matter and cognition: differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia 47, 916927.CrossRefGoogle ScholarPubMed
114. Nowrangi, MA, Lyketsos, CG, Leoutsakos, J-MS, et al. (2013) Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement 9, 519528.CrossRefGoogle ScholarPubMed
115. Penke, L, Muñoz Maniega, S, Murray, C, et al. (2010) A general factor of brain white matter integrity predicts information processing speed in healthy older people. J Neurosci 30, 75697574.CrossRefGoogle ScholarPubMed
116. Perry, ME, McDonald, CR, Hagler, DJ, et al. (2009) White matter tracts associated with set-shifting in healthy aging. Neuropsychologia 47, 28352842.CrossRefGoogle ScholarPubMed
117. Reginold, W, Itorralba, J, Tam, A, et al. (2015) Correlating quantitative tractography at 3T MRI and cognitive tests in healthy older adults. Brain Imaging Behav 10, 12231230.CrossRefGoogle Scholar
118. Salami, A, Eriksson, J & Nyberg, L (2012) Opposing effects of aging on large-scale brain systems for memory encoding and cognitive control. J Neurosci 32, 1074910757.CrossRefGoogle ScholarPubMed
119. Sasson, E, Doniger, GM, Pasternak, O, et al. (2013) White matter correlates of cognitive domains in normal aging with diffusion tensor imaging. Front Neurosci 7, 32.CrossRefGoogle ScholarPubMed
120. Sasson, E, Doniger, GM, Pasternak, O, et al. (2012) Structural correlates of cognitive domains in normal aging with diffusion tensor imaging. Brain Struct Funct 217, 503515.CrossRefGoogle ScholarPubMed
121. Schulze, ET, Geary, EK, Susmaras, TM, et al. (2011) Anatomical correlates of age-related working memory declines. J Aging Res 2011, 606871.CrossRefGoogle ScholarPubMed
122. Voineskos, AN, Rajji, TK, Lobaugh, NJ, et al. (2012) Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling study. Neurobiol Aging 33, 2134.CrossRefGoogle ScholarPubMed
123. Zahr, NM, Rohlfing, T, Pfefferbaum, A, et al. (2009) Problem solving, working memory, and motor correlates of association and commissural fiber bundles in normal aging: a quantitative fiber tracking study. NeuroImage 44, 10501062.CrossRefGoogle ScholarPubMed
124. NHS (UK National Health Service) (2017) B vitamins and folic acid: vitamins and minerals. https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-b/ (accessed May 2018).Google Scholar
125. Moretti, R, Torre, P, Antonello, RM, et al. (2004) Vitamin B12 and folate depletion in cognition: a review. Neurol India 52, 310319.Google ScholarPubMed
126. Vogiatzoglou, A, Smith, SM & Bradley, KM (2008) Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology 71, 826832.CrossRefGoogle ScholarPubMed
127. Selhub, J, Bagley, LC, Miller, J, et al. (2000) B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 71, 614s620s.CrossRefGoogle ScholarPubMed
128. Erickson, KI, Suever, BL, Prakash, RS, et al. (2008) Greater intake of vitamins B6 and B12 spares gray matter in healthy elderly: a voxel-based morphometry study. Brain Res 1199, 2026.CrossRefGoogle ScholarPubMed
129. Tangney, CC, Aggarwal, NT, Li, H, et al. (2011) Vitamin B12, cognition, and brain MRI measures: a cross-sectional examination. Neurology 77, 12761282.CrossRefGoogle ScholarPubMed
130. de Lau, LML, Smith, AD, Refsum, H, et al. (2009) Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 80, 149157.CrossRefGoogle ScholarPubMed
131. Köbe, T, Witte, AV, Schnelle, A, et al. (2016) Vitamin B-12 concentration, memory performance, and hippocampal structure in patients with mild cognitive impairment. Am J Clin Nutr 103, 10451054.CrossRefGoogle ScholarPubMed
132. Ford, AH, Garrido, GJ, Beer, C, et al. (2012) Homocysteine, grey matter and cognitive function in adults with cardiovascular disease. PLOS ONE 7, e33345.CrossRefGoogle ScholarPubMed
133. den Heijer, T, Vermeer, SE, Clarke, R, et al. (2003) Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126, 170175.CrossRefGoogle ScholarPubMed
134. Whalley, LJ, Staff, RT, Murray, AD, et al. (2003) Plasma vitamin C, cholesterol and homocysteine are associated with grey matter volume determined by MRI in non-demented old people. Neurosci Lett 341, 173176.CrossRefGoogle ScholarPubMed
135. Sachdev, PS, Valenzuela, M, Wang, XL, et al. (2002) Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 58, 15391541.CrossRefGoogle ScholarPubMed
136. Seshadri, S, Wolf, PA, Beiser, AS, et al. (2008) Association of plasma total homocysteine levels with subclinical brain injury. Arch Neurol 65, 642649.CrossRefGoogle ScholarPubMed
137. Narayan, SK, Firbank, MJ, Saxby, BK, et al. (2011) Elevated plasma homocysteine is associated with increased brain atrophy rates in older subjects with mild hypertension. Dement Geriatr Cogn Disord 31, 341348.CrossRefGoogle ScholarPubMed
138. Rajagopalan, P, Hua, X, Toga, AW, et al. (2011) Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 22, 391395.CrossRefGoogle ScholarPubMed
139. Madsen, SK, Rajagopalan, P, Joshi, SH, et al. (2015) Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer’s Disease Neuroimaging Initiative. Neurobiol Aging 36, s203s210.CrossRefGoogle ScholarPubMed
140. Firbank, MJ, Narayan, SK, Saxby, BK, et al. (2010) Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int Psychogeriatr 22, 804811.CrossRefGoogle ScholarPubMed
141. Williams, JH, Periera, EAC, Budge, MM, et al. (2002) Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing 31, 440444.CrossRefGoogle ScholarPubMed
142. Feng, L, Isaac, V, Sim, S, et al. (2013) Associations between elevated homocysteine, cognitive impairment, and reduced white matter volume in healthy old adults. Am J Geriatr Psychiatry 21, 164172.CrossRefGoogle ScholarPubMed
143. Raz, N, Yang, Y, Dahle, CL, et al. (2012) Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta 1822, 361369.CrossRefGoogle ScholarPubMed
144. Chee, MWL, Chen, KHM, Zheng, H, et al. (2009) Cognitive function and brain structure correlations in healthy elderly East Asians. NeuroImage 46, 257269.CrossRefGoogle ScholarPubMed
145. Sachdev, P, Parslow, R, Salonikas, C, et al. (2004) Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol 61, 13691376.CrossRefGoogle ScholarPubMed
146. Vermeer, SE, van Dijk, EJ, Koudstaal, PJ, et al. (2002) Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 51, 285289.CrossRefGoogle ScholarPubMed
147. Tan, B, Venketasubramanian, N, Vrooman, H, et al. (2018) Homocysteine and cerebral atrophy: the Epidemiology of Dementia in Singapore Study. J Alzheimer’s Dis 62, 877885.CrossRefGoogle ScholarPubMed
148. Wright, CB, Paik, MC, Brown, TR, et al. (2005) Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 36, 12071211.CrossRefGoogle ScholarPubMed
149. Hsu, J-L, Chen, W-H, Bai, C-H, et al. (2015) Microstructural white matter tissue characteristics are modulated by homocysteine: a diffusion tensor imaging study. PLOS ONE 10, e0116330.CrossRefGoogle ScholarPubMed
150. Bettcher, BM, Watson, CL, Walsh, CM, et al. (2014) Interleukin-6, age, and corpus callosum integrity. PLOS ONE 9, e106521.CrossRefGoogle ScholarPubMed
151. Douaud, G, Refsum, H, de Jager, CA, et al. (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110, 95239528.CrossRefGoogle ScholarPubMed
152. Smith, AD, Smith, SM, de Jager, CA, et al. (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 5, e12244.CrossRefGoogle Scholar
153. Jernerén, F, Elshorbagy, AK, Oulhaj, A, et al. (2015) Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr 102, 215221.CrossRefGoogle Scholar
154. Oulhaj, A, Jernerén, F, Refsum, H, et al. (2016) Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment. J Alzheimer’s Dis 50, 547557.CrossRefGoogle Scholar
155. van der Zwaluw, NL, Brouwer-Brolsma, EM, van de Rest, O, et al. (2016) Folate and vitamin B12-related biomarkers in relation to brain volumes. Nutrients 9, E8.CrossRefGoogle ScholarPubMed
156. Clarke, R, Bennett, D, Parish, S, et al. (2014) Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr 100, 657666.CrossRefGoogle ScholarPubMed
157. McCaddon, A & Miller, JW (2015) Assessing the association between homocysteine and cognition: reflections on Bradford Hill, meta-analyses, and causality. Nutr Rev 73, 723735.CrossRefGoogle Scholar
158. Smith, AD & Refsum, H (2016) Homocysteine, B vitamins, and cognitive impairment. Annu Rev Biochem 36, 211239.Google ScholarPubMed
159. Durga, J, van Boxtel, MP, Schouten, EG, et al. (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369, 208216.CrossRefGoogle ScholarPubMed
160. de Jager, CA, Oulhaj, A, Jacoby, R, et al. (2012) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 27, 592600.CrossRefGoogle ScholarPubMed
161. Chiuve, SE, Giovannucci, EL, Hankinson, SE, et al. (2007) The association between betaine and choline intakes and the plasma concentrations of homocysteine in women. Am J Clin Nutr 86, 10731081.CrossRefGoogle ScholarPubMed
162. Cho, E, Zeisel, SH, Jacques, P, et al. (2006) Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study. Am J Clin Nutr 83, 905911.CrossRefGoogle ScholarPubMed
163. Küllenberg, D, Taylor, LA, Schneider, M, et al. (2012) Health effects of dietary phospholipids. Lipids Health Dis 11, 3.CrossRefGoogle ScholarPubMed
164. Olthof, MR, Brink, EJ, Katan, MB, et al. (2005) Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Am J Clin Nutr 82, 111117.CrossRefGoogle ScholarPubMed
165. Reddan, JM, White, DJ, Macpherson, H, et al. (2018) Glycerophospholipid supplementation as a potential intervention for supporting cerebral structure in older adults. Front Aging Neurosci 10, 49.CrossRefGoogle ScholarPubMed
166. Poly, C, Massaro, JM, Seshadri, S, et al. (2011) The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr 94, 15841591.CrossRefGoogle ScholarPubMed
167. Crespo, D, Megias, M, Fernandez-Viadero, C, et al. (2004) Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioral effects of aging in the rat hippocampus. Ann N Y Acad Sci 1019, 4143.CrossRefGoogle ScholarPubMed
168. Qu, M, Yang, X, Wang, Y, et al. (2016) Docosahexaenoic acid-phosphatidylcholine improves cognitive deficits in an Aβ23–35 Alzheimer’s disease rat model. Curr Top Med Chem 16, 558564.CrossRefGoogle Scholar
169. Luchtman, DW & Song, C (2013) Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 64, 550565.CrossRefGoogle ScholarPubMed
170. Little, SJ, Lynch, MA, Manku, M, et al. (2007) Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis. Prostaglandins Leukot Essent Fatty Acids 77, 155162.CrossRefGoogle Scholar
171. Favreliere, S, Stadelmann-Ingrand, S, Huguet, F, et al. (2000) Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 21, 653660.CrossRefGoogle Scholar
172. McNamara, RK, Liu, Y, Jandacek, R, et al. (2008) The aging human orbitofrontal cortex: decreasing polyunsaturated fatty acid composition and associated increases in lipogenic gene expression and stearoyl-CoA desaturase activity. Prostaglandins Leukot Essent Fatty Acids 78, 293304.CrossRefGoogle ScholarPubMed
173. Norris, SE, Friedrich, MG, Mitchell, TW, et al. (2015) Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. Neurobiol Aging 36, 16591669.CrossRefGoogle ScholarPubMed
174. Fraser, T, Tayler, H & Love, S (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem Res 35, 503513.CrossRefGoogle ScholarPubMed
175. Connor, WE, Neuringer, M & Lin, DS (1990) Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes , and plasma of rhesus monkeys. J Lipid Res 31, 237247.Google ScholarPubMed
176. Barceló-coblijn, G & Murphy, EJ (2009) Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog Lipid Res 48, 355374.CrossRefGoogle Scholar
177. Chen, S & Li, KW (2008) Comparison of molecular species of various transphosphatidylated phosphatidylserine (PS) with bovine cortex PS by mass spectrometry. Chem Phys Lipids 152, 4656.CrossRefGoogle ScholarPubMed
178. Bourre, JM & Dumont, O (2002) The administration of pig brain phospholipids versus soybean phospholipids in the diet during the period of brain development in the rat results in greater increments of brain docosahexaenoic acid. Neurosci Lett 335, 129133.CrossRefGoogle ScholarPubMed
179. Bourre, J, Dumont, O & Durand, G (1993) Brain phospholipids as dietary source of (n-3) polyunsaturated fatty acids for nervous tissue in the rat. J Neurochem 60, 20182028.CrossRefGoogle ScholarPubMed
180. Browning, LM, Walker, CG, Mander, AP, et al. (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 96, 748758.CrossRefGoogle ScholarPubMed
181. Kew, S, Mesa, MD, Tricon, S, et al. (2004) Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am J Clin Nutr 79, 674681.CrossRefGoogle Scholar
182. Popp-Snijders, C, Schouten, J, van Blitterswijk, WJ, et al. (1986) Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) polyunsaturated fatty acids. Maintenance of membrane fluidity. Biochim Biophys Acta 854, 3137.CrossRefGoogle ScholarPubMed
183. Ramprasath, VR, Eyal, I, Zchut, S, et al. (2013) Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis 12, 178.CrossRefGoogle ScholarPubMed
184. Raji, CA, Erickson, KI, Lopez, OL, et al. (2014) Regular fish consumption and age-related brain gray matter loss. Am J Prev Med 47, 444451.CrossRefGoogle ScholarPubMed
185. Del Brutto, OH, Mera, RM, Ha, J-E, et al. (2015) Oily fish consumption is inversely correlated with cerebral microbleeds in community-dwelling older adults: results from the Atahualpa Project. Aging Clin Exp Res 28, 737743.CrossRefGoogle ScholarPubMed
186. Virtanen, JK, Siscovick, DS, Longstreth, WT, et al. (2008) Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. Neurology 71, 439446.CrossRefGoogle ScholarPubMed
187. Titova, OE, Sjögren, P, Brooks, SJ, et al. (2013) Dietary intake of eicosapentaenoic and docosahexaenoic acids is linked to gray matter volume and cognitive function in elderly. Age 35, 14951505.CrossRefGoogle ScholarPubMed
188. Walhovd, KB, Storsve, AB, Westlye, LT, et al. (2014) Blood markers of fatty acids and vitamin D, cardiovascular measures, body mass index, and physical activity relate to longitudinal cortical thinning in normal aging. Neurobiol Aging 35, 10551064.CrossRefGoogle ScholarPubMed
189. Samieri, C, Maillard, P, Crivello, F, et al. (2012) Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology 79, 642650.CrossRefGoogle ScholarPubMed
190. Bowman, GL, Dodge, HH, Mattek, N, et al. (2013) Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Front Aging Neurosci 5, 92.CrossRefGoogle ScholarPubMed
191. Virtanen, JK, Siscovick, DS, Lemaitre, RN, et al. (2013) Circulating omega 3 PUFAS and subclinical brain abnormalities on MRI in older adults. J Am Heart Assoc 2, e000305.CrossRefGoogle ScholarPubMed
192. Harris, WS & Thomas, RM (2010) Biological variability of blood omega-3 biomarkers. Clin Biochem 43, 338340.CrossRefGoogle ScholarPubMed
193. Arab, L (2003) Biomarkers of nutritional exposure and nutritional status biomarkers of fat and fatty acid intake. J Nutr 133, 925932.CrossRefGoogle Scholar
194. Pottala, J, Yaffe, K, Robinson, JG, et al. (2014) Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 82, 435442.Google Scholar
195. Tan, ZS, Harris, WS, Beiser, AS, et al. (2012) Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 78, 658664.CrossRefGoogle ScholarPubMed
196. Zamroziewicz, MK, Paul, EJ, Zwilling, CE, et al. (2017) Predictors of memory in healthy aging: polyunsaturated fatty acid balance and fornix white matter integrity. Aging Dis 8, 372383.CrossRefGoogle ScholarPubMed
197. Daiello, LA, Gongvatana, A, Dunsiger, S, et al. (2015) Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimer’s Dement 11, 226235.CrossRefGoogle ScholarPubMed
198. Witte, AV, Kerti, L, Hermannstädter, HM, et al. (2013) Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 24, 30593068.CrossRefGoogle ScholarPubMed
199. Zhang, Y-P, Miao, R, Li, Q, et al. (2017) Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. J Alzheimer’s Dis 55, 497507.CrossRefGoogle ScholarPubMed
200. van Gelder, BM, Tijhuis, M, Kalmijn, S, et al. (2007) Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85, 11421147.CrossRefGoogle ScholarPubMed
201. Kalmijn, S, van Boxtel, MP, Ocké, M, et al. (2004) Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 62, 275280.CrossRefGoogle ScholarPubMed
202. Kalmijn, S, Feskens, EJM, Launer, LJ, et al. (1997) Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145, 3341.CrossRefGoogle ScholarPubMed
203. Morris, MC, Evans, DA, Bienias, JL, et al. (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940946.CrossRefGoogle ScholarPubMed
204. Nurk, E, Drevon, CA, Refsum, H, et al. (2007) Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 86, 14701478.CrossRefGoogle ScholarPubMed
205. Heude, B, Ducimetière, P & Berr, C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes – The EVA Study. Am J Clin Nutr 77, 803808.CrossRefGoogle ScholarPubMed
206. Samieri, C, Féart, C & Letenneur, L (2008) Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 88, 714721.CrossRefGoogle ScholarPubMed
207. Vauzour, D (2012) Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev 2012, 914273.CrossRefGoogle ScholarPubMed
208. Lephart, ED (2015) Polyphenols and cognitive function. In Diet and Exercise in Cognitive Function and Neurological Diseases, pp. 143161 [T Farooqui and AA Farooqui, editors]. Hoboken, NJ: John Wiley & Sons, Inc.Google Scholar
209. Spencer, JPE, Vauzour, D & Rendeiro, C (2009) Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. Arch Biochem Biophys 492, 19.CrossRefGoogle ScholarPubMed
210. Witte, AV, Kerti, L, Margulies, DS, et al. (2014) Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 34, 78627870.CrossRefGoogle ScholarPubMed
211. Huhn, S, Beyer, F, Zhang, R, et al. (2018) Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults – a randomized controlled trial. NeuroImage 174, 177190.CrossRefGoogle ScholarPubMed
212. Köbe, T, Witte, AV, Schnelle, A, et al. (2017) Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment. Front Neurosci 11, 105.CrossRefGoogle ScholarPubMed
213. Kean, RJ, Lamport, DJ, Dodd, GF, et al. (2015) Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults. Am J Clin Nutr 101, 506514.CrossRefGoogle ScholarPubMed
214. Desideri, G, Kwik-Uribe, C, Grassi, D, et al. (2012) Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension 60, 794801.CrossRefGoogle ScholarPubMed
215. Devore, EE, Kang, JH, Breteler, MMB, et al. (2012) Dietary intakes of berries and flavonoids in relation to cognitive decline. Ann Neurol 72, 135143.CrossRefGoogle ScholarPubMed
216. Krikorian, R, Boesp, EL, Fleck, DE, et al. (2012) Concord grape juice supplementation and neurocognitive function in human aging. J Agric Food Chem 60, 57365742.CrossRefGoogle ScholarPubMed
217. Krikorian, R, Nash, TA, Shidler, MD, et al. (2010) Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr 103, 730734.CrossRefGoogle ScholarPubMed
218. Krikorian, R, Shidler, MD, Nash, TA, et al. (2010) Blueberry supplementation improves memory in older adults. J Agric Food Chem 58, 39964000.CrossRefGoogle ScholarPubMed
219. Nurk, E, Refsum, H, Drevon, CA, et al. (2009) Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 139, 120127.CrossRefGoogle ScholarPubMed
220. Gocmez, SS, Gacar, N, Utkan, T, et al. (2016) Protective effects of resveratrol on aging-induced cognitive impairment in rats. Neurobiol Learn Mem 131, 131136.CrossRefGoogle ScholarPubMed
221. Satizabal, CL, Zhu, YC, Mazoyer, B, et al. (2012) Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 78, 720727.CrossRefGoogle ScholarPubMed
222. Arfanakis, K, Fleischman, DA, Grisot, G, et al. (2013) Systemic inflammation in non-demented elderly human subjects: brain microstructure and cognition. PLOS ONE 8, e73107.CrossRefGoogle ScholarPubMed
223. Bongarzone, ER, Pasquini, JM & Soto, EF (1995) Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J Neurosci Res 41, 213221.CrossRefGoogle ScholarPubMed
224. Brett, R & Rumsby, MG (1994) Susceptibility of myelin glycerophospholipids and sphingolipids to oxidative attack by hydroxyl free radicals as measured by the thiobarbituric acid test. Neurochem Int 24, 241251.CrossRefGoogle ScholarPubMed
225. Chan, PH, Yurko, M & Fishman, RA (1982) Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem 38, 525531.CrossRefGoogle ScholarPubMed
226. Beauchet, O, Celle, S, Roche, F, et al. (2013) Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J Hypertens 31, 15021516.CrossRefGoogle ScholarPubMed
227. Allan, CL, Zsoldos, E, Filippini, N, et al. (2015) Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow-up. Br J Psychiatry 206, 308315.CrossRefGoogle ScholarPubMed
228. Leritz, EC, Salat, DH, Williams, VJ, et al. (2011) Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults. NeuroImage 54, 26592671.CrossRefGoogle Scholar
229. van Sloten, TT, Protogerou, AD, Henry, RMA, et al. (2015) Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: a systematic review and meta-analysis. Neurosci Biobehav Rev 53, 121130.CrossRefGoogle ScholarPubMed
230. Lilamand, M, Vidal, J-S, Plichart, M, et al. (2016) Arterial stiffness and medial temporal lobe atrophy in elders with memory disorders. J Hypertens 34, 13311337.CrossRefGoogle ScholarPubMed
231. Tsao, CW, Beiser, AS, Westwood, AJ, et al. (2013) Relations of arterial stiffness and endothelial function to brain aging in the community. Neurology 81, 984991.CrossRefGoogle Scholar
232. Spencer, JPE, Vafeiadou, K, Williams, RJ, et al. (2012) Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol Aspects Med 33, 8397.CrossRefGoogle ScholarPubMed
233. Nijveldt, RJ, van Nood, E, van Hoorn, DEC, et al. (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74, 418425.CrossRefGoogle ScholarPubMed
234. Cassidy, A, O’Reilly, EJ, Kay, C, et al. (2011) Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr 93, 338347.CrossRefGoogle ScholarPubMed
235. Hooper, L, Kroon, PA, Rimm, EB, et al. (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88, 3850.CrossRefGoogle ScholarPubMed
236. Jennings, A, Welch, AA, Fairweather-Tait, SJ, et al. (2012) Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. Am J Clin Nutr 96, 781788.CrossRefGoogle ScholarPubMed
237. Poulsen, MM, Fjeldborg, K, Ornstrup, MJ, et al. (2015) Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta 1852, 11241136.CrossRefGoogle ScholarPubMed
238. Bellaver, B, Souza, DG, Souza, DO, et al. (2014) Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn, adult and aged Wistar rats. Toxicol Vitr 28, 479484.CrossRefGoogle ScholarPubMed
239. Ma, X, Sun, Z, Liu, Y, et al. (2017) Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. Neural Regen Res 8, 20502059.Google Scholar
240. Liu, Y, Ma, W, Zhang, P, et al. (2016) Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 34, 2734.CrossRefGoogle Scholar
241. Rivera, L, Moron, R, Zarzuelo, A, et al. (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77, 10531063.CrossRefGoogle ScholarPubMed
242. Mithal, A, Wahl, DA, Burckhardt, P, et al. (2009) Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 20, 18071820.CrossRefGoogle ScholarPubMed
243. van Schoor, NM & Lips, P (2011) Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 25, 671680.CrossRefGoogle ScholarPubMed
244. Holick, MF (2007) Vitamin D deficiency. N Engl J Med 357, 266282.CrossRefGoogle ScholarPubMed
245. Becker, JA, Hedden, T, Carmasin, J, et al. (2011) Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 69, 10321042.CrossRefGoogle ScholarPubMed
246. Scott, JA, Braskie, MN, Tosun, D, et al. (2015) Cerebral amyloid and hypertension are independently associated with white matter lesions in elderly. Front Aging Neurosci 7, 221.CrossRefGoogle ScholarPubMed
247. Nosheny, RL, Insel, PS, Truran, D, et al. (2015) Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging 36, 273282.CrossRefGoogle ScholarPubMed
248. Jefferson, AL, Massaro, JM, Wolf, PA, et al. (2007) Inflammatory biomarkers are associated with total brain volume: The Framingham Heart Study. Neurology 68, 10321038.CrossRefGoogle ScholarPubMed
249. Sudheimer, KD, O’Hara, R, Spiegel, D, et al. (2014) Cortisol, cytokines, and hippocampal volume interactions in the elderly. Front Aging Neurosci 6, 153.CrossRefGoogle ScholarPubMed
250. Briones, TL & Darwish, H (2012) Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation 9, 244.CrossRefGoogle ScholarPubMed
251. Durk, MR, Han, K, Chow, ECY, et al. (2014) 1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer’s disease. J Neurosci 34, 70917101.CrossRefGoogle ScholarPubMed
252. Ito, S, Ohtsuki, S, Nezu, Y, et al. (2011) 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide (1–40) from mouse brain across the blood–brain barrier. Fluids Barriers CNS 8, 20.CrossRefGoogle ScholarPubMed
253. Yu, J, Gattoni-celli, M, Zhu, H, et al. (2011) Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J Alzheimer’s Dis 25, 295307.CrossRefGoogle ScholarPubMed
254. Moore, ME, Piazza, A, McCartney, Y, et al. (2005) Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. Biochem Soc Trans 33, 573577.CrossRefGoogle ScholarPubMed
255. Schleithoff, SS, Zittermann, A, Tenderich, G, et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83, 754759.CrossRefGoogle ScholarPubMed
256. Zhang, Y, Leung, DYM, Richers, BN, et al. (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 188, 21272135.CrossRefGoogle ScholarPubMed
257. Annweiler, C, Annweiler, T, Bartha, R, et al. (2014) Vitamin D and white matter abnormalities in older adults: a cross-sectional neuroimaging study. Eur J Neurol 21, 14361442.CrossRefGoogle ScholarPubMed
258. Annweiler, C, Bartha, R, Karras, SN, et al. (2015) Vitamin D and white matter abnormalities in older adults: a quantitative volumetric analysis of brain MRI. Exp Gerontol 63, 4147.CrossRefGoogle ScholarPubMed
259. Annweiler, C, Montero-Odasso, M, Hachinski, V, et al. (2013) Vitamin D concentration and lateral cerebral ventricle volume in older adults. Mol Nutr Food Res 57, 267276.CrossRefGoogle ScholarPubMed
260. Prager, JM, Thomas, C, Ankenbrandt, WJ, et al. (2014) Association of white matter hyperintensities with low serum 25-hydroxyvitamin D levels. Am J Neuroradiol 35, 11451149.CrossRefGoogle ScholarPubMed
261. Moon, Y, Moon, W, Kwon, H, et al. (2015) Vitamin D deficiency disrupts neuronal integrity in cognitively impaired patients. J Alzheimer’s Dis 45, 10891096.CrossRefGoogle ScholarPubMed
262. Karakis, I, Pase, MP, Beiser, A, et al. (2016) Association of serum vitamin D with the risk of incident dementia and subclinical indices of brain aging: the Framingham Heart Study. J Alzheimer’s Dis 51, 451461.CrossRefGoogle ScholarPubMed
263. van der Schaft, J, Koek, HL, Dijkstra, E, et al. (2013) The association between vitamin D and cognition: a systematic review. Ageing Res Rev 12, 10131023.CrossRefGoogle ScholarPubMed
264. Moon, JH, Lim, S, Han, JW, et al. (2015) Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol 83, 3642.CrossRefGoogle Scholar
265. Miller, JW, Harvey, DJ, Beckett, LA, et al. (2015) Vitamin D status and rates of cognitive decline in a multiethnic cohort of older adults. JAMA Neurol 72, 12951303.CrossRefGoogle Scholar
266. Perna, L, Mons, U, Kliegel, M, et al. (2014) Serum 25-hydroxyvitamin D and cognitive decline: a longitudinal study among non-demented older adults. Dement Geriatr Cogn Disord 38, 254263.CrossRefGoogle ScholarPubMed
267. Berti, V, Murray, J, Davies, M, et al. (2015) Nutrient patterns and brain biomarkers of Alzheimer’s disease in cognitively normal individuals. J Nutr Health Aging 19, 413423.CrossRefGoogle ScholarPubMed
268. Bowman, GL, Howieson, D, Traber, MG, et al. (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 78, 241249.CrossRefGoogle ScholarPubMed
269. Gu, Y, Vorburger, RS, Gazes, Y, et al. (2016) White matter integrity as a mediator in the relationship between dietary nutrients and cognition in the elderly. Ann Neurol 79, 10141025.CrossRefGoogle ScholarPubMed
270. Kesse-guyot, E, Andreeva, VA, Lassale, C, et al. (2013) Mediterranean diet and cognitive function: a French study. Am J Clin Nutr 97, 369376.Google ScholarPubMed
271. Gardener, H, Scarmeas, N, Gu, Y, et al. (2012) Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Arch Neurol 69, 251256.CrossRefGoogle ScholarPubMed
272. Morris, MC, Tangney, CC, Wang, Y, et al. (2015) MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimer’s Dement 11, 10071014.CrossRefGoogle ScholarPubMed
273. Hardman, RJ, Kennedy, G, Macpherson, H, et al. (2016) Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials. Front Nutr 3, 22.CrossRefGoogle ScholarPubMed
274. Morris, MC, Tangney, CC, Wang, Y, et al. (2015) MIND diet slows cognitive decline with aging. Alzheimer’s Dement 11, 10151022.CrossRefGoogle ScholarPubMed
275. Mosconi, L, Murray, J, Tsui, WH, et al. (2014) Mediterranean Diet and magnetic resonance imaging-assessed brain atrophy in cognitively normal individuals at risk for Alzheimer’s disease. J Prev Alzheimer’s Dis 1, 2332.Google ScholarPubMed
276. Staubo, SC, Aakre, JA, Vemuri, P, et al. (2017) Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer’s Dement 13, 168177.CrossRefGoogle ScholarPubMed
277. Gu, Y, Brickman, AM, Stern, Y, et al. (2015) Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology 85, 17441751.CrossRefGoogle Scholar
278. Pelletier, A, Barul, C & Catherine, F (2015) Mediterranean diet and preserved brain structural connectivity in older subjects. Alzheimer’s Dement 11, 10231031.CrossRefGoogle ScholarPubMed
279. Luciano, M, Corley, J, Cox, SR, et al. (2017) Mediterranean-type diet and brain structural change from 73 to 76 years in a Scottish cohort. Neurology 88, 449456.CrossRefGoogle Scholar
280. Titova, OE, Ax, E, Brooks, SJ, et al. (2013) Mediterranean diet habits in older individuals: associations with cognitive functioning and brain volumes. Exp Gerontol 48, 14431448.CrossRefGoogle ScholarPubMed
281. de Bruin, EA, Hilleke, EHP, Bijl, S, et al. (2005) Associations between alcohol intake and brain volumes in male and female moderate drinkers. Alcohol Clin Exp Res 29, 656663.CrossRefGoogle ScholarPubMed
282. Sachdev, PS, Chen, X, Wen, W, et al. (2008) Light to moderate alcohol use is associated with increased cortical gray matter in middle-aged men: a voxel-based morphometric study. Psychiatry Res Neuroimaging 163, 6169.CrossRefGoogle ScholarPubMed
283. den Heijer, T, Vermeer, SE, van Dijk, EJ, et al. (2004) Alcohol intake in relation to brain magnetic resonance imaging findings in older persons without dementia. Am J Clin Nutr 80, 992997.CrossRefGoogle ScholarPubMed
284. Topiwala, A, Allan, CL, Valkanova, V, et al. (2017) Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ 357, j2353.CrossRefGoogle ScholarPubMed
285. Taki, Y, Kinomura, S, Sato, K, et al. (2006) Both global gray matter volume and regional gray matter volume negatively correlate with lifetime alcohol intake in non-alcohol-dependent Japanese men: a volumetric analysis and a voxel-based morphometry. Alcohol Clin Exp Res 30, 10451050.CrossRefGoogle Scholar
286. Paul, CA, Au, R, Fredman, L, et al. (2008) Association of alcohol consumption with brain volume in the Framingham Study. Arch Neurol 65, 13631367.CrossRefGoogle ScholarPubMed
287. Gu, Y, Scarmeas, N, Eaton, E, et al. (2014) Alcohol intake and brain structure in a multiethnic elderly cohort. Clin Nutr 33, 662667.CrossRefGoogle Scholar
288. Jacka, FN, Cherbuin, N, Anstey, KJ, et al. (2015) Western diet is associated with a smaller hippocampus: a longitudinal investigation. BMC Med 13, 215.CrossRefGoogle ScholarPubMed
289. Croll, PH, Voortman, T, Ikram, MA, et al. (2018) Better diet quality relates to larger brain tissue volumes: The Rotterdam Study. Neurology 90, e2166e2173.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Randomised clinical trials examining cerebral structure following chronic nutritional supplementation in older adults without dementia (presented in reverse chronological order and by nutrient type)

Supplementary material: File

Reddan et al. Supplementary Material

Table S1

Download Reddan et al. Supplementary Material(File)
File 84 KB
You have Access
5
Cited by